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Abstract 
Abstract of thesis entitled: Combining CGH and high-resolution 
allelotyping study for ependymoma submitted by Zheng Pingpin for the 
degree of Master of Philosophy at the Chinese University of Hong Kong 
in August 2000 
Supervisor: Professor Ho-Keung Ng 
Ependymomas are rare glial neoplasms that are predominantly found in 
children and young adults. So far little is known about the 
tumorigenesis of these tumors. The objective of my study was to 
provide an overview of genetic aberrations in ependymomas using two 
genome-wide screening techniques, comparative genomic hybridization 
(CGH) and high-resolution allelotype analyses. CGH was performed on 
28 ependymomas, of which 16 cases were further analyzed by 
allelotyping. Genomic/allelic imbalances on one or more chromosomal 
arms were detected in all of the cases for both tests. The frequencies 
ranged from 11% (llq) to 71% (22q) for CGH and from 6.3% (Iq and 
18p) to 75% (16p) for allelotyping. The most frequent chromosomal 
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alterations, in order of decreasing frequencies, were losses of 
chromosomes 22q (71%), 16 (57%), 17 (46%), 6 (39%), 19q (32%), 20q 
(32%) and gains of 5q (46%), 12q (39%), 7q (36%)，9q (36%), 4q (32%) 
for CGH; while losses of chromosomes 16p (75%), 22q (62.5%), 16q 
(56.3%), 17p (56.3%)，19p (56.3%), 19q (56.3%), 20p (56.3%), and 20q 
(56.3%) were found using allelotyping. Multiple overlapping small 
duplication and deletion regions were also identified. The duplication 
regions were delineated at 4q23-28, 5q21-22, 7ql 1.2-31.2, 9ql2-32, 12q 
15-24.1, and the deletion regions were mapped at 6q24=qter, 16pl2-13.1, 
16q21-22, 17pl3, 19qll-13.3, 20ql3.2-13.3, 22ql3.1-13.3. The data 
correlate with previous reports on frequent losses of chromosomes 6, 17 
and 22q in ependymomas as well as further identifying frequent losses of 
chromosomes 16, 19, 20 and gains of chromosomes 4 and 5 as new 
findings in ependymomas. Frequent duplications or deletions of these 
regions suggest the presence of oncogene(s) or tumor suppressor gene(s) 
in these regions that may be involved in the development of 
ependymomas. These findings indicate a greater degree of genomic 
duplication and loss in ependymomas than has been previously reported. 
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The deletion regions can be further narrowed down by fine mapping to 
facilitate the cloning of potential candidate gene(s) that might be 
involved in ependymomas. Hence by elucidating the genetic events 
underlying the development of ependymomas, we hope to provide ways 
for improvement in diagnosis, treatment and prognosis of ependymomas. 
Key words: Oncogene Tumor suppressor gene Comparative 
genomic hybridization Ependymoma Allelotyping 
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摘 要 
室管膜瘤是一种不常見的膠質瘤。主要發生在儿童和青年人。至今甚少 
知其形成机制。本文采用比較基因組雜交（Comparative Genomic Hybridization 




度從11% ( l l q )至 7 1 % (22q) ； HRA資料提示發生頻率爲6.3% ( I q及 1 8 p )至 
76% (16p) .在CGH資料，最常見的染色體丟失依次爲22q (71%), 16 (57%), 17 
(46%), 6 (39%), 19q (32), 20q (32%)；複製依次爲 5q (46%), 12q (39%), 7q (36%), 
9q (36%), 4q (32%).而在HRA，最常見的染色體丟失依次爲16p (75%), 22q 
(62.5%), 16q (56.3%), 17p (56.3%), 19p (56.3), 19q (56.3%), 20p (56.3%), 20q 
( 5 6 . 3 % ) �染色體 4和 5複製以及 1 6 , 19, 20丟失作爲常見的異常發現以往未曾 
被報道。多個微小丟失和複製區被圈定。根據CGH,微小複製區爲4q23-28, 
5q21-22, 7qlL2-31.2, 9ql2-32, 12ql5-24.1�根據 HRA,微小丟失區爲 6q24-qter, 
16pl2-13.1, 16q21-22, 17pl3, 19qll-13.3, 20ql3.2-13.3, 22ql3.1-13.3�這些經常發 
生基因複製或丟失的區域將意味著腫瘤抑制基因或致癌基因存在于此，它們可以 








關 鍵 詞 ： 致 癌 基 因 腫 瘤 抑 制 基 因 比 較 基 因 組 雜 交 室 管 膜 瘤 
高分辨率等位基因譜分析 
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Chapter I Introduction 
LI. Preface 
There are many methods involved in human cancer research. These 
methods may usually be summarized into five cascade of levels, including 
clinical, pathological, cytogenetic, molecular cytogenetic and molecular 
genetic studies. All these methods have been used in ependymoma studies. 
Although numerous studies have been performed and there were some 
findings in ependymomas, yet most of these studies were limited in 
clinico-pathological and cytogenetic levels. The description of non-random 
chromosomal aberrations in tumors is a vital clue in the identification of genes 
driving the development and/or progression of a malignancy. However, 
classic cytogenetics only allows the detection of gross genetic changes for the 
selected clones and cannot "see" different cell populations. More subtle 
comparative genomic hybridization (CGH) allows assessment of DNA copy 
number changes in the whole of a tumor compared to normal tissue DNA for 
different cell populations. The evolving chromosomal clues can then be used 
for targeted linkage analysis in an attempt to identify tumor suppressor genes 
(TSG) and oncogenes. CGH incorporates the sensitivity of in situ techniques 
and overcomes many of the drawbacks of conventional cytogenetic analysis. 
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However, CGH study for ependymomas was very rare and the existing two 
studies only correlated to pediatric patients (1, 2). Furthermore, most of 
allelic loss studies only included analyses for individual or several 
chromosomes with small panels of microsatellite markers. Occasionally 
several cases were analyzed in all chromosomes, but the markers used 
covered chromosomes at a low density (3, 4). Therefore smaller regions of 
allelic imbalance were inevitably missed or cannot be detected. So far an 
overview of 22 autosomes at a high-resolution level has not been reported. 
Based on such a current status, a comprehensive method in molecular 
cytogenetic and molecular genetic levels (combined comparative genomic 
hybridization and high-resolution allelotyping) was embarked on my study 
for ependymoma in both adult and pediatric patients. The study will be the 
first comprehensive screening for all the autosomal regions in ependymomas. 
1.2. Overview of Carcinogenesis 
Each tumor has its specific carcinogenic process. In order to better 
understand these processes, it is necessary to introduce an overview of tumor 
carcinogenesis. Carcinogenesis is a multi-step process at both the phenotypic 
and genetic level. The results of cumulative multiple genetic changes result 
in the activation of oncogenes and the inactivation of TSGs. It is the 
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differential expression of these critical genes and their downstream effectors 
that enable cells to override growth controls and undergo carcinogenesis (5, 6). 
The accumulation of genetic alterations contributes to tumor progression 
including metastatic phenotype and grade of malignancy (7). 
The pathological changes that arise in cancer, whether caused by a 
single gene mutation or multiple genetic alterations, are essentially driven by 
changes in gene expression (5, 6). Tumor progression is widely regarded as 
multiple processes that begin with a single altered cell whose clonal 
descendants are forced to undertake a program of increasing deregulated 
growth (8, 9). TSGs (recessive oncogenes) and oncogenes may drive the 
tumor cells through the stages of this process. The normal cellular function 
of these genes is thought to be suppression of cell proliferation. Inactivation 
of both copies of a TSG may contribute to neoplastic transformation by 
removing a normal constraint to cell growth (10). 
In operational terms cancer may be defined as a set of disorders in 
which there are three pivotal abnormalities in cell behavior (11): 1) A 
disturbance in the mechanisms that control cell proliferation; 2) A 
disturbance in cell differentiation; 3) A disturbance in the normal 
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relationship between the proliferating cells and the surrounding connective 
tissue stroma. The latter abnormality is expressed in the form of invasiveness 
and, ultimately metastasis, and is, therefore a fundamental part of the 
malignant phenotype. These carcinogenic mechanisms are mediated through 
abnormalities affecting four classes of normal regulatory genes (11)——the 
growth-promoting proto-oncogenes; the growth-inhibiting cancer suppressor 
genes (antioncogene); genes that regulate programmed cell death, or 
apoptosis; mutator genes that regulate repair of damaged DNA. 
Mutant alleles of proto-oncogenes are considered dominant because 
they transform cells despite the presence of their normal counterpart. In 
contrast, both normal alleles of the TSGs must be damaged for 
transformation to occur [(p53 gene may be an exceptional case (See Section 
1.3 in detail)], so this family of genes is sometimes referred as recessive 
oncogenes (11). Genes that regulate apoptosis may be dominant, as are 
proto-oncogenes, or they may behave as cancer suppressor genes. The DNA 
repair genes (mutator genes) affect cell proliferation or survival indirectly by 
influencing the ability of the organism to repair nonlelhal damage in other 
genes, including proto-oncogenes, tumor suppressor genes, and genes that 
regulate apoptosis (10’ 11). Mutator malformation of DNA repair genes can 
predispose to widespread mutations in the genome and hence to neoplastic 
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transformation (8,11). Currently, more than 100 proto-oncogenes have been 
identified, although not all of these have been found to be mutated in human 
neoplasms. The number of TSGs so far identified is much smaller (11). 
1. 3. Oncogenes 
Proto-oncogenes form part of the normal genome and they 
contribute to neoplastic transformation only if they are qualitatively or 
quantitatively altered. When they are not abnormally activated, the term 
cellular proto-oncogene is used (11); when they are altered, the term 
oncogene is used (11). The fusion of proto-oncogenes with parts of other 
genes forms novel genes. These novel genes are called chimeric genes 
(11). The oncogene paradigm developed has proved to be particularly 
powerful in generating an explanation of cancer at the molecular level. 
Proto-oncogenes are usually involved in the normal growth, maturation, and 
differentiation of cells, including those of the central nervous system (12). 
The overexpression of unaltered proto-oncogenes via a variety of mechanisms 
which include amplification and translocation of proto-oncogene to a region 
where its transcription is significantly increased. The classification of 
oncogenes based on their collaborative powers in transformation assay was 
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paralleled in a striking way by a totally distinct system of categorizing these 
genes: classifying them by the intracellular localization of their respective 
gene-products (13). 
Oncogene can be functionally classified into four classes (6): 1. Class 
I: These are growth factors, such as c-sis; 2. Class II: These are 
transmembrane receptors, such as c-erbBl, c-erbB2, c-mos, trk, met, 
fins, ros\ 3. Class III: These are intracellular transducers, such as ras, gsp; 
4. Class IV: These are nuclear transcription factors, such as myc, gli, jun, 
fos. The evolutionary history of a tumor cell clone is demarcated by a series 
of oncogene activations, each of which confines on the tumor cells some of 
the phenotypes that in aggregate constitute fully malignant behavior (13). 
1.4. Tumor Suppressor Genes (TSGs) 
Tumor suppressor genes (TSGs) are defined as genes whose functional 
inactivation contributed to tumor development. They can be functionally 
grouped into three categories (14): 1. Gatekeeper TSG: It includes all direct 
inhibitors of cell growth (suppressing proliferation, inducing apoptosis or 
promoting differentiation), which is further subdivided into initiation 
gatekeeper, progression gatekeeper or metastasis gatekeeper; 2. Caretaker 
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TSG: It acts indirectly to suppress growth by ensuring the fidelity of the DNA 
code through effective repair of DNA damage or prevention of genomic 
instability such as microsatellite or chromosome instability; 3. Landscaper 
TSG: It acts by modulating the microenvironment in which tumor cells grow, 
perhaps by direct/indirect regulation of extracellular matrix proteins, cell 
surface markers, adhesion proteins, or secreted growth/survival factors. 
Mutation or loss of these genes results in loss of their growth-inhibiting 
functions, so that unfettered cell proliferation is more likely to occur. It is this 
loss of function that contributes to oncogenesis. 
Recent cancer research has focused on delineating the chromosomal 
location of putative TSG involved in carcinogenesis (15). This work has 
led to the discovery of specific TSGs, or regions containing putative TSGs, 
involved in many cancers, e.g. retinoblastoma, breast, lung, bladder, and 
colon carcinomas (16-20). In this model of carcinogenesis, loss or 
inactivation of a TSG can be due to several mechanisms: point mutations, 
small deletions, mitotic recombination, and loss of entire chromosomes. 
Cytogenetic studies of tumors can detect only gross chromosomal losses 
and large deletions. At a molecular level, loss of heterozygosity (LOH) 
studies, using polymorphic microsatellite markers, can detect the large 
deletion as well as small regions that may harbor such TSGs (21). The 
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inactivation of multiple tumor suppressor genes, through deletion and/or point 
mutation, is thought to be critical during tumorigenesis such as colorectal 
cancer, retinoblastoma, breast cancer etc (11, 22-24). A series of TSGs (RB， 
WTl, TP53, NFl, NF2, DCC，and APQ with widely differing functions have 
been isolated. 
In the examples studied to date, inactivation of both copies of a TSG in 
somatic cells are required for tumorigenesis. This may occur by epigenetic or 
genetic mechanisms, but in most cases mutations have been identified in both 
alleles of a TSG in relevant tumors (25). It is worthwhile mentioning that the 
p53 gene is a dominant negative gene, hence it is not necessary to have 
mutations in both alleles for carcinogenesis (11). In most instances, 
mutations that inactivate both copies of the p53 gene are acquired in somatic 
cells. It is uncommon for some individuals to inherit a mutantp53 allele. As 
with the Rb gene, inheritance of one mutant allele predisposes individuals to 
develop malignant tumors. Such individuals are at a high risk of developing a 
wide variety of tumors, including carcinomas, sarcomas, lymphomas, and 
brain tumors (11). Following mutation to one allele of a TSG, the cell is 
heterozygous for the mutation and subsequent deletion of the second allele 
generates homozygosity for this mutation. The objective of any study of 
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allele loss is to pinpoint the chromosomal locations that are likely to contain 
TSGs. 
1.5. Detection of Oncogenes and Tumor Suppressor Genes 
1.5.1. Detection of Oncogenes 
Gene amplification is one of the major mechanism of oncogene 
activation in tumorigenesis. It is therefore of considerable interest to develop 
strategies for identifying amplified genes and determining their expression 
levels in cancer. Numerous quantitative methods based on polymerase chain 
reaction (PCR) have been developed to measure gene copy number (26-28). 
Until recently, gene amplification has been detected by Southern blot 
hybridization, PCR, flurescence in situ hybridization (FISH) with 
gene-specific probes (6, 29). 
Southern blot hybridization is a technique that involves transferring 
restriction enzyme-digested DNA fragments from an agarose gel to a 
nitrocellulose filter on which they can be hybridized to a complementary 
DNA. Southern blot was discovered by Professor EM Southern. The 
structure and the relative copy number of a gene can be analyzed using the 
technique. 
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PCR was developed much later than Southern blot, and has rapidly 
found a wide range of applications. It allows the production of large 
quantities of a specific region of DNA without recourse to cloning, and is 
fast, relatively simple to perform. Quantitation is performed by comparing 
the PCR signal of the specific template with the PCR signals obtained with 
known concentrations of the competitor (the internal standard) (30) 
CGH, developed almost eight years ago, was the first molecular 
cytogenetic tool that allowed comprehensive analysis of the entire genome 
and has now become one of the most popular genome scanning techniques for 
detection of amplified regions in tumor DNA (31 )• The major advantages of 
CGH over other techniques are listed as follows: 1. It allows analysis of the 
total genome for loss or gain of genetic material in one single experiment; 2. It 
does not require metaphase from the tumor cells; 3. It may “see” different 
populations of cells more than those identified by cytogenetic analysis. The 
technique is based on a modified in situ hybridization, in which differentially 
fluorescently labeled test (green) and reference (red) DNAs are co-hybridized 
to normal metaphase spreads (Figure 1). Copy-number differences between 
the test and reference genomes are seen as green: red fluorescence intensity 
differences on the metaphase chromosomes. Quantitation of test to reference 
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DNA fluorescence ratios along all chromosomes are performed using a digital 
image analysis system. DNA gains and amplification in the test DNA are 
seen as chromosomal regions with an increased fluorescence ratio, while 
losses and deletions result in a reduced ratio. However, CGH has limited 
sensitivity and resolution (32) (see section 1.11). In addition, the 
identification of the specific target gene within an amplicon defined by CGH 
remains daunting because of the limited mapping resolution provided by the 
metaphase chromosomes (29) (see section Lll) . 
DNA microarray technology offers the possibility to replace the 
target metaphase chromosomes with arrays of DNA clones with defined 
chromosomal location immobilized on a microscope slide (33, 34). Arrayed 
fragments of cloned genomic DNAs have been used for this purpose (33, 34). 
DNA-based CGH-array surveys of copy number by hybridizing labeled 
DNAs to arrays of cloned probes on a glass slide (35). These CGH array 
techniques allow amplification detection on the resolution level equal to the 
length of the arrayed DNA clones < 100 kb and substantially increase the 
resolution (5-20Mb) of the conventional CGH technique (29). 
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Several strategies have been used successfully to identify new TSGs. 
The positional approaches of representational difference analysis (RDA) or 
genome scanning using sequence-tagged sites (STS) have been successfully 
applied in the identification of TSG (36). Loss of heterozygosity (LOH) 
detection by restriction fragment length polymorphism (RFLP) has been an 
outdated method because of its low-resolution and its requirement of a large 
quantity of DNA. In RFLP a probe is used to detect DNA fragments of 
various size due to difference in restriction fragment lengths. Polymorphism 
is an altered DNA base sequence in gene, either between the two alleles in one 
individual or between different individuals, that occurs naturallly in the 
population and usually does not lead to changes in the function of the coded 
protein (37). It is an early study method to detect LOH. Most of RFLP loci 
were diallelic with skewed allele frequencies and low level of heterozygosity 
(informativeness) (38). The problem of informativeness was resolved by the 
discovery of variable number of tandem repeat (VNTR) or microsatellite 
markers (e.g. mono-, di-, tri- and tetra- nucleotides). These markers are 
polymorphic DNA loci that contain a repeated nucleotide sequence. The 
commonest type of VNTRs is dinucleotides. The repeat unit can be 2-7 
nucleotides in length. The number of nucleotides per repeat unit is the same 
for a majority of repeats within a microsatellite locus. VNTRs, characterized 
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by variation in copy number of short, 15-50bp，tandemly repeated DNA 
sequences, are found to be frequent in the human genome with average 
heterozygosities of 60-90% and the average heterozygosities are 
approximately evenly distributed over the human genome (38). 
The so-called microsatellite analysis is referred to the following: 
Microsatellite loci are PGR amplified and PCR products are then analyzed 
by electrophoresis to separate the alleles according to sizes. 
PCR-based microsatellite analysis has the following advantages over 
conventional methods such as RFLP for detecting allele loss: 1. The small 
size of microsatellite loci improves the chance of obtaining a result, 
particularly for samples containing minute amounts of DNA; 2. The small 
size range of microsatellite loci makes them ideal candidates for 
co-amplification while keeping all amplified alleles smaller than 350 base 
pairs. Many microsatellite loci can therefore be typed in a single PCR; 3. 
Microsatellite alleles have discrete sizes, allowing for simplified 
interpretation of results; 4. PCR-based tests are rapid, giving results in 24 
hours or less. PCR-based tests are easy to standardize and automate, ensuring 
reproducible results. The above outline was summarized from the web-site 
of Perkin-Elmer company. 
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LOH refers to the observation of a single allele at particular genetic 
locus or loci (homozygous or hemizygous) in a specimen, generally a benign 
or cancerous lesion or pre-cancerous lesion, arising in an individual who is 
heterozygous for the same locus or loci in their normal tissue. The normal or 
"constitutional" genotype is generally determined in DNA isolated from 
peripheral lymphocytes or from histologically normal tissue adjacent to the 
pathological lesion of interest (38). LOH mapping is based on the 
observation that TSGs are frequently inactivated by an intragenic mutation 
in one allele accompanied by loss of the second allele. Mechanisms for loss 
of constitutional heteozygosity in somatic cells are shown in Figure 2. A 
study of LOH on all chromosome arms has been termed an allelotyping (by 
analogy with karyotype). Allelotypes of many types of tumors have now 
been published (39-43) and it is clear that tumors arising in different tissues 
have distinctive allelotypes. Some regions of deletion are shared by many 
tumors, while others are unique to a specific type of tumor or subset of tumors. 
As low marker density has been used in the past, it is likely that some 
important tumor suppressor loci have remained undetected, particularly if 
deletions are small. Nevertheless, many regions have been identified and the 
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1.6. Profiles of Oncogenes/TSGs and Molecualr Subtype about Astrocytic 
Tumors 
In the malignant progression of astrocytic tumors, it has been 
shown that accumulation of multiple genetic lesions underlie the 
above-mentioned neoplastic processes. These lesions included mutations 
of p53, pi 6, Rb, and phosphatase and tensin homolog {PTEN), as well 
as amplification of the cyclin-dependent kinase {CDK4) and epidermal 
growth factor receptor (EGFR) genes (44, 45). Although these known 
genetic abnormalities have been well documented in the formation of the 
most malignant brain tumors, glioblastoma, recent insight into the extent of 
gene expression differences underlying malignancy reveals that hundreds of 
gene transcripts may be expressed at significantly different levels between 
normal and neoplastic cells (46). Therefore, there is considerable room for 
the identification of novel genes that are differentially expressed in brain 
tumor cells to further our understanding of the complex molecular basis of 
these neurological cancers. Furthermore, this endeavor has direct clinical 
relevance if combined with the development of innovative rational therapies 
that specifically target these differentially expressed gene products. 
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Recent studies have demonstrated the feasibility of molecular 
parameters for subdividing glioblastoma multiform (GBM), 
oligodendrogliomas, and oligoastrocytomas into genetically distinct tumor 
groups that may be associated with a different prognosis and response to 
therapy (47-49). However, such a molecular subdivision on ependymomas 
has not been reported so far. To date only a few data are available linking 
possible TSG and oncogene to ependymoma. Genome-wide survey of 
genetic alterations in ependymomas has been limited. Two studies reported 
the use of CGH for chromosome imbalances but only pediatric ependymomas 
were involved (1, 2). Blacker et al (3) studied chromosome loss by 
allelotyping in ependymomas. However, they only used a few markers for 
each chromosome examined (3). Recently allelotyping analysis of 466 brain 
tumors with 129 microsatellite markers, containing 7 WHO grade II 
ependymomas was performed (4). Although the density of the used markers 
in this study were more than the allelotyping study done by Blacker et al (3), 
there was still more room for improvement with need of increased 
microsatellite markers. In the current study, a high-resolution allelotyping 
using 382 microsatellite markers with average genetic distance 
(lOcM) was performed in ependymoma. 
Clinical data from previous reports seemed to support the hypothesis 
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of distinct biological subsets of ependymoma. Intramedullary spinal 
ependymomas differ from intracranial ependymomas with respect to age at 
diagnosis and to prognosis, which are likely to include genetically different 
tumor entities, as has already been shown for glioblastomas and 
oligoastrocytomas (50). 
Over the past few years, considerable effort has been expended to 
characterize genetic abnormalities in cancer, the general idea being that 
tumor genotyping would be valuable in defining cancer phenotype. 
Ependymomas have very strong intratumoral phenotypic/genetic 
heterogeneity. Such a heterogeneity has made some classical histological 
criteria fail to correlate with clinical behavior as well as relating directly to its 
variability at the genetic level. The variability is characterized by the 
presence of heterogenous cell clones with polyploid and hyperploid cell 
populations (51). Tumor genotyping could be a valuable approach to 
define ependymoma molecular subtypes, perhaps there is an association 
between the number of genetic alterations observed in a tumor, which may 
allow a better understanding of the biological behavior of these tumors and 
clarify their prognostic grouping. Likewise, molecular subdivision of 
ependymomas may be of importance for future therapeutic procedures. 
- Zheng PP 20 
1.7. Intratumoral Heterogeneity and Microsatellite Instability 
Many tumors have apparent intratumoral phenotypic and cytogenetic 
heterogeneities (clonal heterogeneity). It has been widely accepted that, 
with tumor progression, subpopulations of neoplastic cells with different 
biological characteristics successively evolve within a tumor that has initially 
arisen from a single progenitor cell. This concept is known as intratumoral 
heterogeneity (52). The concept can be applied to gliomas as well as other 
solid tumors. Intratumoral heterogeneity of histological appearance seems to 
be linked to genetic alterations in each cell, which is important for 
understanding differences in the biological behavior of tumors for assessing 
the response to treatment (53, 54). 
Microsatellite instability (MSI) referred to as replication errors or the 
mutator phenotype, is recognized as genome-wide alterations in repetitive 
DNA sequences (38, 55). Several mismatch repair genes have been 
identified {hMLHl, hMSH2, hPMSl, hPMS2 and hMSH6), and the failure 
to repair deletions or mutations in critical TSGs can provide affected clones 
with a growth advantage (6). 
1.8. Outline of Ependymoma 
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Ependymomas belong to a subclass of glioma and are heterogeneous 
with regards to morphology, localization, age at first clinical manifestation, 
prognosis, cytogenetic and molecular genetic findings. They originate from 
the ependymal cells that form the lining of the ventricular surfaces of the brain 
and the central canal of the spinal cord, and constitute approximately 3-5% of 
central nervous system tumors (56). Although ependymomas may occur at 
sites throughout the central nervous system, they are more common at sites 
adjacent to the ventricles. 
Ependymomas may occur in all age groups but predominantly in 
children and adolescents. They constitute approximately 9% of childhood 
brain tumor (57). Patients with intramedullary spinal ependymoma are, on 
average, approximately 40 years of age (57-60). These spinal tumors are 
associated with a significantly better prognosis than their intracranial 
counterpart (57-59, 61). Half of the pediatric patients has a mean age at 
diagnosis of 5 to 6 yr . Nearly 90% of pediatric ependymomas are intracranial 
(IC) and only 10% are intraspinal (IS). On the other hand, over 60% of 
ependymomas arise in the spinal cord or filum terminale, and only 40% are IC 
in adult (52, 62-64). Currently, surgery and radiotherapy are the standard 
treatment for ependymomas with a 5 year survival rate of 20-30% (65). The 
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role of chemotherapy in ependymoma remains unknown (66). At the 
cytogenetic, molecular cytogenetic and molecular genetic levels, no specific 
recurrent abnormality for this tumor has been identified. 
L9. Clinicopathological Factors and Prognosis 
1.9.1. Histology and Grading(2000) 
Ependymomas are composed predominantly of neoplastic ependymal 
cells. They express a great variability of morphological appearances, which 
have given rise to several histologic variants without strong evidence of 
correlation with clinical outcome (66). The recognition of the malignant 
variant is neither easy nor reproducible, and the criteria by which an 
ependymoma classified as malignant remain ambiguous. In the literature, 
the percentage of the anaplastic variant ranges from 7-89% (67, 68). These 
studies illustrate the difficulty in achieving a consensus in discriminating 
between low-grade and anaplastic ependymoma. 
According to the latest World Health Organization (WHO) 
classification (2000) (69)，ependymal neoplasms are histologically 
classified into four major types and three grades as well as some variants. 
They are listed as below: 
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1. WHO Grade I (Myxopapillary ependymoma). 
2. WHO Grade I (Subependymoma). 
3. WHO Grade II: Ependymoma. 
4. WHO Grade III: Anaplastic ependymoma. 
Figure 3 shows the histology of a representative case of WHO grade II 
in light microscopic level. Electronic microscopic hallmarks are usually 
characterized by complex intercellular junctions, microlumina, surface 
microvilli, cilia and microrosettes, which may help to differentiate some 
difficulty cases from others at the light microscopic level. 
1.9.2. Prognostic Factors 
Several prognostic factors have been assessed in recent studies on 
ependymomas. Age, sex, tumor location, extent of surgery and treatment 
modality were frequently analyzed (62, 63, 67, 70-87) and the findings are 
shown below. 
1.9.2.1. Age/Sex/Location 
Young age is often reported as an adverse prognostic factor (56, 57, 
62, 71-75, 81, 88-90). However, there has been conflicting views whether 
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long been recognized that ependymomas located in the spinal cord have a 
better outcome than intracranial ependymomas (57, 61). Some ectopic 
ependymomas have been reported and these tumors occurred in ovary and 
broad ligament (94, 95). 
1.9.2.2. Extent of Resection 
The extent of resection has a positive influence on survival rate of 
ependymoma (66). In a recent report, Pollack et al (88) assessed the 
postoperative computer tomography (CT) or magnetic resonance imaging 
(MRI) scan of patients with no obvious residual disease and further reported 
a survival rate of 10 years after surgery. In addition, Healey et al (67) 
reported patients with radiological residue. In this group, no patients had 
a survival long than 10 years. In these two series, the 10-year survival rate 
in patients with negative postoperative imaging was 75% and 71% 
respectively, 
1.9.2.3. Radiotherapy and Chemotherapy 
Radiotherapy is commonly considered as the standard complementary 
treatment of intracranial ependymomas. Most studies indicated better 
survival in patients receiving post-operative radiation (57, 88, 90, 96-98). 
The role of chemotherapy in ependymoma still remains unknown. All 
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studies involved chemotherapy failed to show a survival advantage (68, 76, 
88, 87，99-101). 
1.9.2.4. Histology 
Histology as a prognositic factor failed to establish a link 
between anaplasia and poor outcome (66). Numerous studies have yielded 
conflicting results regarding the prognostic value of standard histological 
criteria (hypercelluarity, nuclear pleomorphism, necrosis, endothelial 
proliferation and mitoses) used for the diagnosis of anaplastic ependymomas 
(57, 67, 72, 73, 75，92, 95’ 96, 102-109). However, some 
immunohistochemical markers such as glial fibrillary acidic protein (GFAP), 
human telomerase RNA (hTR), bromodeoxyuridine (BrdU), MIB-1 (Ki-67) 
appeared to correlate with the prognosis (109-114). 
In one study, a large number of GFAP immunoreactive cells 
correlated with a better outcome (79). Telomerase activity is detected in 
proliferating stem cells and in many neoplastic cells and may represent the 
essential feature of cellular immortalization (115-118). Its expression is an 
important biological marker for many tumors, independent of other 
histological criteria of tumor grade, also indicate tumor aggressiveness earlier 
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than conventional hispathological criteria (110). BrdU labeling is used at 
surgery through intravenous infusion to label tumor cells in the DNA 
synthesis phase (112). Tumors with high BrdU labeling index (LI), 
irrespective of their histologic features, grow faster and are clinically more 
aggressive than tumors with low LI and have a strong tendency to recur (111, 
112). 
Immunostaining using the MIB-1 monoclonal antibody specific for a 
nuclear proliferation antigen has proven to be another important tool in the 
study of cell kinetics in brain tumors (113). High MIB-1 index 
immunolabeling might be objective indicators of high grade ependymomas 
that do not otherwise meet ependymoma routine histologic criteria for high 
grade (113). 
1.10. Cytogenetic, Molecular Cytogenetic and Molecular Studies 
About 155 cases of ependymomas have been cy to genetically analyzed 
(56, 119, 120) and their genetic altered profiles are listed in Table 1. It is 
apparent from these studies that ependymomas, even in the low grade variants, 
often have complex cytogenetic abnormalities. No specific recurrent genetic 
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abnormality has been identified so far (56，119，120). However, several 
structural or numeric abnormalities have been described involving 
chromosomes 6，7，8, 9, 10，11, 13，17 and 22 ( 56, 121- 123). The most 
frequent altered chromosomes were chromosomes 22 and 17 (3, 120, 124). 
Approximately 30% of ependymomas have monosomy of chromosome 22, 
and the other cases showed deletions or translocations involving 22q (120, 
123, 125-133), although there is considerable variability in the frequency of 
this finding in various studies. Monosomy 22 occurs with approximately the 
same frequency in both adult and pediatric ependymomas and is not more 
frequent in anaplastic ependymoma (56), suggesting loss of chromosome 22 
is an early event in the tumorigenesis of ependymomas. 
Several cytogenetic and molecular genetic studies have demonstrated 
22q deletion in ependymoma (119, 129, 133-137). The NF2 gene is located 
at chromosome 22ql2 (14). The gene spans 110 kb, comprises 17 exons 
and encodes a 587-amino acid protein, designated merlin or schwannomin. 
NF2 shows significant homology to several members of family of proteins 
residing at interface-linking cytoskeletal components moesin, ezrin, and 
radixin, with proteins in the cell membrane (138, 139). Neurofibromatosis 
type 2 is a dominantly inherited condition characterized by bilateral acoustic 
neuromas. NF2 occurs with an incidence of 1 in 40,000 live births (140). In 
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Table 1. A Profile Of Genetic Aberrations For Ependymomas (Review) 
Frequency Chromosome Loss Gain * Reference No. 
Frequent 6 + 1,2, 121-123, 153, 169 
17 + 121, 126, 153, 154, 156 
22 + 116, 117, 120, 122-124, 126-130 
Less frequent 7 + 5 1 ， 1 2 2 , 169, 192，225-228，232 
9 + 116,117 
10 + 126, 127, 121, 153 
11 + 116, 117, 123, 128, 192 
12 + 116,117 
13 + 123, 127, 128, 119, 121, 153 
Rare 4 + 127 
5 + 116，122 
16 + 1,3, 121，123, 128, 193’ 194 
19 + 202 
20 + 191 
*, see the list of references. 
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addition, an increased incidence of meningiomas, gliomas, and ependymomas 
was found in these patients (140-142). About 2-5% of ependymomas with 
NF2 were observed, suggesting the involvement of the NF2 locus in some 
ependymomas (143). Due to the increased incidence of ependymomas in 
neurofibromatosis type 2, NF2 was suggested to be a candidate TSG in 
ependymal neoplasms. There were also some reports about ependymomas 
supporting NF2 suppressor gene located at 22ql2 (50, 135, 144, 145). 
However, there were some studies that found a different locus on 
chromosome 22 to be involved in ependymal tumorigenesis, suggesting that 
chromosome 22q harbors another ependymoma tumor suppressor gene (134, 
146). 
In one study, the authors did not find any NF2 mutations in 15 
intracranial ependymomas (50), suggesting NF2 gene is not a primary tumor 
suppressor gene in some ependymomas. There were several data that 
implicated the NP2 gene as the target of 22q allelic loss in at least some 
intraspinal ependymomas (50, 135, 144). Rubio, Ebert, Hoang-Xuan et al 
detected and screened 29 intraspinal ependymomas , in which LOH and NF2 
mutations on chromosome 22 were found in 12/29 cases (50, 135, 144). These 
data suggest that NF2 mutation is specific to intramedullary spinal 
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ependymomas which constitute a distinct molecular variant characterized by 
an altered NF2 gene on chromosome 22 (50). Alternatively, the lack of 
mutations in the remainder of intraspinal ependymomas may imply a second 
ependymoma suppressor gene in chromosome 22 or that NF2 mutations may 
occur in nonexonic portion of the gene, such as in promoter, or in addition, 
alternatively spliced exons (135). In addition, the lack of mutations in the 
remainder of the ependymomas also may be due to problems in the screening 
method since SSCP (single strand conformation polymorphism) may not 
detect all point mutations and is not an adequate means of identifying larger 
genomic deletions (135). Such larger genomic deletions have already been 
noted in several NF2 patients (138). 
Recently, Ebert et al (1999) resolved this problem by reporting that 
mutation in NF2 is specifically associated with the WHO grade II 
ependymomas that have a spinal localization (50). In their study, NF2 
mutations were detected in 6 of 14 intramedullary spinal WHO grade II ( E 
II), but in 0 of 15 intracranial E II (50). Such data indicate that NF2 plays 
an important role in the oncogenesis of WHO grade II spinal ependymomas 
and further suggest that ependymoma is compromised of genetically different 
tumor entities (50). 
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However, some studies have concluded that the putative ependymoma 
TSG on chromosome 22 is independent of or separate from 
the NF2 gene (132-134, 144, 147). The presence of schwannomin (NF2 
gene product) in some ependymomas also indicated that additional genes 
are likely to play a role in the tumorigenesis of these tumor (148). INIl 
/hSNFS/SMARCBl TSG is mapped at 22ql 1.2 locus, which encodes a 
member of the chromatin-remodelling SWI/SNF multiprotein complex 
(149-154). The putative TSG showing homozygous deletions and truncating 
mutations in pediatric malignant rhabdoid tumor (MRTs) has been identified 
(154). The observation ofbi-allelic alterations of INI 1 /hSNFS/SMARCB 1 in 
MRTs suggests that loss-of-function andmutations of 
INI 1 /hSNF5/SMARCB1 contribute to oncogenesis (154). It will be of 
interest to determine whether INI 1 /hSNF5/SMARCB 1 TSG is involved in 
ependymomas. 
Another chromosome of interest in the study of ependymoma is 
chromosome 17 because of the presence of a well-known tumor suppressor 
genep53 (155). This gene is located at chromosome 17pl3.1 region. 
Monosomy 17 has been described as a frequent event in ependymoma (124, 
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129, 146, 156). However, the occurrence ofp53 mutations in both adult and 
pediatric ependymoma is rare (146, 156-161). In 5 studies, the cases of 
detectedp53 mutation were 1/18, 3/26, 1/6, 0/15, 1/31 respectively (146, 
158-161). In a microsatellite analysis study done by von Haken et al (1996), 
50% ependymoma sample harbored 17p arm loss, preferentially being distal 
to the p53 locus (146). Deletions in chromosome 17q23 have also been 
reported based on cytogenetic analysis and LOH study (129, 156). These 
results suggest that at least two TSGs may be involved in the development of 
ependymoma on chromosome 17, residing on p and q arms respectively. 
Chromosome 6 is another interesting chromosome involved in 
ependymomas. Loss of chromosome 6 is a common genetic aberration found 
in pediatric ependymoma (1，162). Reardon et al reported 23 pediatric 
ependymomas and concluded loss of chromosome 6 was the most common 
genetic aberration in pediatric ependymomas (1). This was the sole paper 
for CGH analysis about ependymomas so far. However, other studies showed 
loss of chromosome 6 occurs at similar frequencies in both pediatric and adult 
patients (124-126, 156). Another study of the pediatric ependymoma for 
CGH analysis was reported in American Association for Cancer Research 
(AACR) meeting (1999) (2). It also did not refer loss of chromosome 6 as 
the frequently affected chromosome in pediatric ependymomas (2). 
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There has been reported cases of linking chromosome 11 to 
ependymomas ( 129,163), possibly involving several oncogenes reported on 
chromosome l l q such as bcl-1, HST and INT-2g (131). However the role of 
these genes in ependymomas remains uncertain (56). Regarding other 
chromosomes, the reported cases were very limited. Well-documented data 
will be required from a relatively large panels of ependymoma analysis for a 
conclusion. 
Lll, Advantages and Disadvantages of the Research Methods 
Although there is generally a good concordance for CGH and 
allelotyping, one must be aware of limitations inherent to each technique so as 
to interpret results correctly. There are two major common limitations for 
both CGH and allelotyping analysis (38): 1. CGH and allelotyping analysis 
are techniques which average the genomic changes being assayed over the 
population of cells comprising a sample and are limited by the technical 
ability to separate tumor cells from normal cells within the specimen; 2. Both 
are insensitive to true biological heterogeneity within the population of tumor 
cells. 
There are significant advantages and disadvantages in using CGH 
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analysis. An advantage is that it permits the analysis of the whole genome in 
one experiment. Also this allows detection of deletion(s) and /or gain(s) not 
revealed by microsatellite analysis due to the unavailability of appropriate 
marker(s) in the region(s) concerned (164). A limitation of CGH is that it can 
only identify losses or gains in comparatively large chromosome regions 
(about�10-12Mb) (31, 165). 
Sensitivity of the method is limited by how much normal tissue is 
present in the sample (e.g. normal brain or blood vessels) or by genetic 
heterogeneity within tumor cells. Sensitivity is also affected by the 
physical size of the aberration, smaller regions (less than l-2Mb) are more 
difficult to be detected by CGH (165). Furthermore, CGH is insensitive to 
genetic aberrations that do not alter the DNA copy number, such as 
translocation or inversion. Therefore, CGH analysis may not detect the 
absolute prevalence of genetic abnormalities at a particular locus. 
In short, the CGH technology is limited mainly by relative and 
particularly the flizziness of the deletion borderline. Its sensitivity is 
limited, and deletions smaller than l-2Mb cannot usually be detected (165). 
However, such deletions can be easily detected by the appropriate 
microsatellite markers. Moreover, microsatellite analysis can reveal 
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meiotic recombination that do not result in net loss or gain of DNA or 
chromosome non-disjunction/reduplication, neither of which cannot be 
detected by CGH (166, 167). However, microsatellite analysis cannot 
distinguish between deletion(s) and gain(s), which can be detected by CGH. 
Also the molecular nature of the chromosomal events, translocations, 
rearrangements, etc., that lead to LOH as well as loss of tumor suppressor 
loci is not differentiated by microsatellite analysis (36, 38, 168 )• It remains 
possible that structural considerations account for hotspots of localized LOH 
without the involvement of a tumor suppressor gene. Such regions could be 
suspected by a high number of breakpoints causing high local rates of LOH, 
and thereby need not reflect the outcome of clonal selection. There is 
currently no method for ruling out this possibility (36). 
Chapter II. Aims of the Study 
Although numerous studies have been performed and there were some 
findings in ependymomas, yet most of studies were limited in 
clinico-pathological and cytogenetic levels. Molecular cytogenetic (CGH 
and FISH) study was rare (1, 2). Some molecular genetic studies only 
included analyses for individual or several chromosomes with small panel of 
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microsatellite markers. The existing two studies for whole genome analyses 
also only involved low-density markers (3, 4). So far, an overview of 22 
autosomes at a high-resolution level has not been reported. 
The current study hypothesized that the development of ependymoma, 
like other solid tumors, is a multi-step process that involves inactivation of 
TSG and activation of oncogenes located on several chromosomes. These 
genetic alterations can be detected using molecular genetic techniques such 
as CGH and high-resolution allelotyping. Thus the aims of the current study 
on ependymomas were as follows: 
1. To screen for the allelic duplication and loss for the 22 autosomes using 
CGH and high-resolution allelotyping. 
2. To determine the frequency of chromosomal losses and gains. 
3. To determine the extent of deleted as well as amplified regions on 
all autosomal arms. 
4. To attempt to identify novel regions of deletion and amplification. 
Chapter III Materials and Methods 
III. 1. Tumor Samples and DNA Preparation 
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III. 1 • 1 Tumor Samples 
Twenty-eight primary ependymomas, obtained from 20 adult and 
pediatric patients, were included in this study. None of the patients had 
clinical stigma of spontaneous NF2 or metastatic disease at diagnosis. The 
samples all came from the first operations without prior radiation therapy or 
chemotherapy. All tumors were classified as WHO grade II ependymomas 
according to the recent WHO criteria (69). The mean ages for the adult and 
childhood groups were 37.2 yrs (range 22-7lyrs) and 11.1 yrs (range 2-16 
yrs), respectively (Table 2). In the adult group, 11(55%) ependymomas were 
intracranial while 9 (45%) were intraspinal; whereas in the pediatric group, 7 
(88%) childhood ependymomas were intracranial and only a single tumor was 
located in the spinal cord (Table 2). The actual tumor blocks for 
intraoperative frozen tissue were used for this study and therefore contained 
diagnostic tissue. Tumor tissues obtained from surgery were frozen in liquid 
nitrogen and stored at -80°C until use. The tissue for DNA extraction was 
histologically verified to consist of a minimum of 80% tumors in each case. 
III. 1.2 DNA Preparation 
DNA was extracted from 5-7 cryostat tissue sections (30]jm/each) by 
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Table 2. Clinical data and CGH findings associated with 28 primary ependymomas. 
Case Tumor 
No. Sex/Age Site^ Chromosomal losses'' Chromosomal gains 
1 F/40 C4-T4 3,4ql3-24/4q31.2-qter, 6, 8p/8ql 1.2-2l.l/8q 2, 5pl2-14/5ql 1.2-21/5q31-34, 7pl5/ 
24.1-qter,13q, 14q, 22q 7ql 1.2-31.2, 9pl2-21/9ql3-33, 12p 
11.2-12/12ql2-23, 15ql 1.2-25, 17p/ 
17ql 1.2-23, 18ql 1.2-21, 20ql 1.2-12 
2 F/31 FL 16pl3.1-pter/16q23-qter, 17pl2-pter/17q22-qter, 5pl2-13/5ql 1.2-21,9 
18, 19pl3.3/19q, 20ql3.1-qter, 22q 
3 F/31 FL lp36.1-pter, 4pl5.2-pter, 5q33-qter, 6p22-qter, 9, 17p/17ql 1.2-23 
13q, 14q31-qter, 15q26-qter, 18, 22ql3-qter 
4 F/22 PF 1,2, 10q24-qter，16, 17,20,22q 4,5ql2-33,7pl 1.2-15.3/7ql 1.21-34, 
9, 12，14ql 1.2-22, 15q, 18 
5 M/40 Cl-5 13q33-qter, 16pl3.2-pter/16q22-qter, 19,22q 7,12 
6 M/31 T7-10 1,3,6, 13q, 14q, 22q 2,5ql 1.2-22,9, 12p/12ql2-24.1, 18 
7 M/28 4thv 3p/3ql3.3-qter, 6, 10, 16pl2.3-pter/16q21-qter, Ipl2-31/lq21-31,4pl2-15.3/4q23-
17, 22ql2-qter 28, 5pl2-15.2/5ql 1.2-23, 8, 9p, 
13q21.3-33, 18p 
8 M/42 C8-T1 lq41-qter, 6 7ql 1.2-35，16，19p/19ql3.1,22q 
9 M/27 Cl-6 16p/16ql 1.2-22.3，17p, 19,22q 4ql2-34,5ql3-31, 12ql5-2 
10 M/49 4th V 2p24-pter, 8ql3-21.1, 13q, 22q 5ql4-23,7,9q21, 12 
11 F/47 4th V 6, 16，17qll.2-21, 18p, 19p/19ql2-13.3, 21qll.2 4, 7q22-35, 8q, 9p21-pter/9q 12-32, 
-22.2, 22q 12ql4-21 
12 M/35 T9-L3 — llq21-qter, 16q21-qter,18,20pl2-13/ 
20ql3.1-qter, 22ql2-qter 
13 M/38 C3-7 1，3,6, 13q, 14q, 20ql2-qter, 22q 2,5p/5ql 1.2-23,9, 12p/12ql2-24.1, 
18 
14 F/71 4th V lp34.3-pter, 16, 17, 19,20q, 22q — 
15 M/26 LV 3,6, 10, 16pl3.1-pter/16ql2.2-qter, 17pl2-pter/ 4p, 5p/5ql 1.2-32, 8, 13ql3-21 
17q21.3-qter, 22q 
16 F/36 Cl-6 Ip34.1-pter/lq42-qter, 15ql 1.2-25, 16, 17, 2p22-35,4ql2-23/4q31.3-34,5q21-
18, 19, 20, 22q 23, 6ql6-26, 7, 12p/12ql2-24.1, 
13q21-32 
17 M/35 Cl-2 13q22-qter 15q, 16p, 17p, 18pl 1.2-11.31, 19, 
21q 
18 M/36 LTL 9, 16q 4,6ql2-26,7ql 1.2-34, 12, 14ql2-31, 
17ql 1.2-24 
19 M/36 4th V 2, 3，6，8, 10pl2.3-pter/10q22-23, 13q22-qter, Iq, 4，5, 7, 9, 11, 14q, 15q, 18 
16q22-qter, 17q22-qter, 21q 
20 M/42 4th V 4q31.3-qter,21q22-qter, 22q — 
21 F/16 RPL 10pl3-pter/10q26-qter, 12q23-qter, 14q31-qter, 21qll.2-21 
15q22-qter, 16pl2-pter, 17q22-qter, 20ql2-qter, 
22ql3-qter 
22 F/13 4th V 16pl3.1-pter, 22q — 
23 F/8 4th V lp33-pter, 14q, 19,20q, 22q Iq, 13q21-qter, 21qll.2-21 
24 F/12 T11-S3 12q23-qter, 17ql 1.2-22 2q22-24,5q21-22 
25 M/12 4thv 8, 9, lOp/lOql 1.2-25, 13ql2-22, 14ql 1.2-23, lpl3-22, 2pl 1.2-2l/2ql 1.2 
16q22-qter, 21q -31/2q33-qter, 3，6p/6q23-26, 7, 
12, 17, 18 
26 F/12 PL 5pl2-15.1/5ql5-22,6ql5-21/6q26-qter — 
27 F/3 CB lp35-pter, 9q32-qter, 10q25-qter, 12q24.1-qter 2q23-34, 4q23-28, 5ql5-22, 6ql5-
16,17,19, 20q, 22q 21, 13ql3-21 
28 F/12 PF 16pll.2-13.2/16ql 1.2-23.1, 17, 18p/18q22-qter, 13ql3-21 
19p/19ql2-13.2, 20ql 1.2-13.2, 22q 
a CB, cerebrum; FL, frontal lobe; LTL, left temporal lobe; LV, lateral ventricle; PF, posterior fossa; PL, parietal lobe; 
RPL, right parietal lobe; 4* V, the fourth ventricle, 
b ---, averaged fluorescence ratio below the threshold level. 
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conventional proteinase K and phenol-chloroform extraction (169). Detailed 
protocol is described as follows. Frozen tissue sections in 15 ml centrifuge 
tubes were washed 3 to 4 times with phosphate-buffer saline (PBS) to remove 
the OTC compound, and then centrifuged at 3200 rpm for 20 minutes at room 
temperature. To the tissue pellet, 3.8ml STE [O.IM Saline, 0.05M Tris (pH 
7.5) and ImM EDTA], 40^1 proteinase K (lOmg/ml) and 0.2ml 10% sodium 
dodecyl sulfate (SDS) were added . The mixture was incubated at 55°C 
overnight. To remove protein from the lysate, 4ml of 
phenol/chloroform/isoamyl alcohol (v/v) (25: 24: 1) (pH 8.0) was added to 
the tube containing the lysate. The tube was mixed by inversion for 10-15 
minutes. Then the solution was kept in -20°C for at least 10 minutes. 
Separation of phenol/chloroform/isoamyl alcohol from the aqueous 
layer was achieved by centrifugation at 4000 rpm for 20 minutes at room 
temperature. The top aqueous layer containing the DNA was collected. 
The phenol-chloroform extraction step was repeatedly performed (3-4 times) 
until the interface was clear. To precipitate DNA, 1/10 volume (0.4ml) of 
3M sodium acetate and 2-2.5 volumes (8 to 10 ml) of prechilled 100% 
ethanol were added to the aqueous solution. The genomic DNA usually 
appeared as precipitates immediately after gentle mixing of the solution. 
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The solution was centrifuged at 4000 rpm for 20 minutes to pellet the 
precipitated DNA. The supernatant was discarded and the white DNA pellet 
appeared at the bottom of the tube was washed with prechilled 70% ethanol. 
The DNA pellet was then transferred using sterile pipet tips to 1.5 ml 
Eppendorf tube and was dried at room temperature. Finally, appropriate 
amount of sterile deionized water (100-300|li1) was added to dissolve the DNA. 
To facilitate DNA dissolution, the DNA was incubated in a 37°C water bath 
for at least 2 hours. DNA concentration was determined with a 
spectrophotometer (Pharmacia Gene Quant). 
The blood samples for CGH analyses came from the peripheral 
blood of the normal individual volunteers, whrease the blood samples 
(control) for allelotyping analyses were the tumor matched peripheral blood. 
All blood samples were frozen at -80 ° C. Blood was collected into EDTA 
tubes (There are two kinds of tubes for collecting the blood. One is the EDTA 
tube; another is the heparin tube. The latter interferes with DNA digestion. 
Therefore EDTA tube should be used in collecting blood for DNA 
extraction) (170). Frozen blood samples were thawed at room temperature for 
about 1 hr, and then transferred to a 15 ml centrifuge tube prior to DNA 
extraction. To the blood, 6ml of IX PBS were added to lyse the red 
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blood cells. The tube was centrifuged at 3200 rmp for 20 minutes. A 
reddish tissue pellet was revealed at the bottom of the tube and the 
supernatant was discarded. These steps were repeated until the pellet 
became whitish, and this indicated that most of red cells had been removed. 
DNA extraction using proteinase K and phenol/chloroform/isoamyl alcohol 
was performed as described above for tumor DNA. 
III.2. Comparative genomic hybridization 
III.2.1. Metaphase Preparations 
Phytohemagglutinin (PHA)-stimulated normal male or female whole 
blood was cultured in medium for synchronized metaphase spread production 
by using standard protocol of our laboratory (171). The protocol is outlined as 
follows: 5ml fresh blood was cultured in the mixture containing RPMI 1640, 
10% heat-inactivated fetal bovine serum, 100 lU/ml penicillin G and 100 
|ig/ml streptomycin mixture (l%)(Sigma), L-glutamine (1%), PHA 
(0.5mg/ml)(Sigma). The culture cells were incubated at 37°C for 72 hrs with 
slight agitation. After 72 hrs, 500|il colcemid (10|Lig/ml) was added to the 
culture cells, and then the cells was further incubated at 37°C for 20 minutes. 
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After incubation, the cells were centrifliged for 10 minutes at 1500 rpm. 40ml 
of hypotonic 0.05 M KCl was added drop by drop, mixing it intermittently to 
the cell pellet. The cells were again incubated at 37°C for 20 minutes 
followed by centrifUgation. Afterwards, 40 ml fresh, prechilled fixative 
solution [methonal: acidic acetate (3:1, v/v)] was added to the cell pellet drop 
by drop (use first 5 ml to completely dissolve the pellet) and allowed to mix 
well, and then spun at 1500 rpm for 10 minutes. The cells were washed 5-6 
times with fixative until the pellet was white in color and spread onto clean 
dry slides. 
Each slide was screened for the presence of longer metaphase that were 
evenly spread using a Nikon phase-contrast microscope. The slides were 
stored at -20° C until use. Prior to CGH, slides were treated with RNAse and 
pepsin [The final concentration for the RNAse was (O.lmg/ml) and the pepsin 
(0.05mg/ml)] and denatured in 70% formamide/2XSSC at 68-70�C. Finally 
the slides were dehydrated using an graded ethanol series (70%, 90% and 
100%). 
IIL2.2. DNA Labeling/Hybridization/Detection 
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CGH was performed as previously used in our laboratory (171). 
The tumor DNA and normal reference DNA were labeled with 
biotin-16-dUTP and digoxigenin (dig)-l 1-dUTP (Boehringer Mannheim, 
Mannheim, Germany), respectively. Labeling was performed by nick 
translation with the conditions adjusted to have probe size ranging from 400 
to 2000bp. Eight hundred nanograms each of biotinylated tumor DNA and 
sex mismatched dig-labeled normal reference DNA were co-precipitated with 
40|ig of Cot-1 DNA (BRL life Sciences, Gaihersburg, MD). 
The mixed probe was dissolved in I2\il of hybridization buffer [50% 
formamide, 20% dextran sulphate, and 2XSSC(NaCl and sodium citrate)] and 
applied to slide with metaphase cell spread prepared from the blood of a 
healthy donor. Hybridization was carried out at 37°C for 3 days. 
Biotinylated DNA was detected through avidin conjugated-fluorescein 
isothiocyanate (FITC, Vector Laboratories, Burlingame, CA) whereas 
dig-labeled DNA was detected using anti-digoxigenin rhodamine (Sigma 
Chemical Co., St. Louis, MO). Chromosomes were counterstained with 
anti-fade solution containing 4,6-diamino-2-phenylindole (DAPI; Vector 
Laboratories) for identification. In each experiment, sex-mismatched normal 
DNA was used as the competing probe for target sites on metaphases as well 
as the internal control for the specificity of chromosomal gains and losses. 
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As a result, only the 22 autosomes were analyzed. 
IIL2.3. Digital Image Analysis 
Digital image analysis was performed using the Digital Image 
System ISIS3 (Metasystems GmbH, Sand hausen, Germany). Digital images 
of rhodamine, FITC and DAPI fluorescence were captured, independently 
through three separate band pass filters, by a cooled CCD camera connected 
onto a Zeiss fluorescence microscope (Jena, Germany). In each case, at least 
fifteen metaphases were acquired and analyzed. A rough discrimination 
between objects (metaphase chromosomes, interphase nuclei etc) and 
background was made in the image segmentation step. The next step was to 
discriminate the objects found in the DAPI image. The chromosomes were 
cut out, cut up, glued together, moved and set at any angle. Touching 
chromosomes were separated, and artifacts and interphase cells were deleted. 
Overlapping chromosomes and chromosomes influenced by artifacts were 
rejected. All operations which are done in the DAPI image, were 
simultaneous executed for the FITC and TRJTC image automatically. 
After the segmentation step a karyogram form was drawn and the 
chromosomes were automatically vertically arranged. There is a Compare 
Function for the software, which allows for switching between the DAPI. 
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FITC, TRITC and FITC/TRITC ratio images. The FITC/TRITC ratio image 
was especially helpful tool for chromosome classification because the pseudo 
coloration of the ratio image made it easy to identify homologous 
chromosomes. 
The average fluorescence ratios along each of the 22 autosomes 
were calculated with a digital imaging system ISIS3 (Metassystems GmbH, 
Sandhausen, Germany). The threshold levels for the identification of 
chromosomal imbalances were set at 0.75 and 1.25 respectively. Any ratio 
profiles below 0.75 were scored as losses and ratio profiles exceeding 1.25 
were counted as gains. These values were established on the basis of CGH 
experiments using normal DNA and DNA from cell lines with known 
chromosomal aberrations. Heterochromatic chromosome regions in the 
centromeric and paracentromeric parts of some chromosomes (1,9 and 16), 
and the short arms of the acrocentric chromosomes were not included in the 
analysis due to suppression of the Cot-1 DNA. 
IIL3 High-resolution allelotying (microsatellite analysis) 
III.3.1 General Outline 
Allelotype was preformed in 16 cases of ependymomas. All DNA (16 
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cases) came from the remaining DNA after the CGH experiments. These 
cases had both tumor and blood samples. 12 were adult cases while 4 were 
pediatric cases. Three hundred and eighty-two microsatellite loci signed for 
22 autosomes were examined in this high-resolution allelotyping. 
Fluorescent dye labeled primer pairs flanking polymorphic microsatellite loci 
were obtained from Applied Biosystems (Foster City, CA). 
All primer pairs used were from the ABI PRISM Linkage Mapping Set 
MD-2 (http://www.pebio.com/ab/apply/dr/lmsv2/). The average interval of 
the loci was about lOcM. The markers were organized into 28 panels, 
which were displayed in Table 3. Each panel contained between 10-20 
fluorescent dye-labeled primer pairs that generate PGR products that can 
be pooled and detected in a single gel lane or capillary injection. Overlapping 
alleles were distinguished by labeling with three different fluorescent dyes, 
[FAM], [HEX], and [NED], which were displayed on the ABI PRISM®377 
as blue, green and yellow respectively. 
III.3.2 Multiplex PCR 
Multiplex Polymerase chain reaction (PCR) was set up to examine 
2 loci in each reaction. PCR was performed in a 7.5 |li1 reaction volume, 
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Table 3. Fluorescence Markers Used in This Study 
Ch 1 Ch2 Ch3 Ch 4 Ch 5 Ch 6 Ch 7 Ch 8 
D1S468 D2S319 D3S1297 D4S412 D5S1981 D6S1574 D7S531 D8S264 
D1S214 D2S2211 D3S1304 D4S2935 D5S630 D6S309 D7S517 D8S277 
D1S450 D2S162 D3S1263 D4S403 D5S416 D6S470 D7S513 D8S550 
D1S2667 D2S168 D3S2338 D4S419 D5S419 D6S289 D7S507 D8S549 
D1S2697 D2S305 D3S1266 D4S391 D5S426 D6S422 D7S493 D8S258 
D1S199 D2S165 D3S1277 D4S405 D5S418 D6S276 D7S516 D8S1771 
D1S234 D2S367 D3S1289 D4S1592 D5S407 D6S1610 D7S484 D8S505 
D1S255 D2S2259 D3S1300 D4S392 D5S647 D6S257 D7S510 D8S285 
D1S797 D2S391 D3S1285 D4S2964 D5S424 D6S460 D7S519 D8S260 
D1S2890 D2S337 D3S1566 D4S1534 D5S641 D6S462 D7S502 D8S270 
D1S230 D2S2368 D3S3681 D4S414 D5S428 D6S434 D7S669 D8S1784 
D1S2841 D2S286 D3S1271 D4S1572 D5S644 D6S287 D7S630 D8S514 
D1S207 D2S2333 D3S1278 D4S406 D5S433 D6S262 D7S657 D8S28S 
D1S2868 D2S2216 D3S1267 D4S402 D5S2027 D6S292 D7S515 D8S272 
D1S206 D2S160 D3S1292 D4S1575 D5S471 D6S308 D7S486 
D1S2726 D2S347 D3S1569 D4S424 D5S2115 D6S441 D7S530 Ch 14 
D1S252 D2S112 D3S1279 D4S413 D5S436 D6S1581 D7S640 D14S261 
D1S498 D2S2313 D3S1569 D4S1597 D5S410 D6S264 D7S684 D14S283 
D1S484 D2S142 D3S11614 D4S1539 D5S422 D6S446 D7S661 D14S275 
D1S2878 D2S2330 D3S1565 D4S415 D5S400 D6S281 D7S636 D14S70 
D1S196 D2S335 D3S1262 D4S1535 D5S408 D7S798 D14S288 
D1S218 D2S364 D3S1580 D4S426 Ch 12 D7S2465 D14S276 
D1S238 D2S117 D3S1601 Ch 11 D12S352 D14S63 
D1S413 D2S325 D3S1311 Ch 10 D11S4046 D12S99 Ch 13 D14S258 
D1S249 D2S2382 D10S249 D11S1338 D12S336 D13S175 D14S74 
D1S425 D2S126 Ch 9 D10S591 D11S902 D12S364 D13S217 D14S68 
D1S213 D2S396 D9S288 D10S189 D11S904 D12S310 D13S171 D14S280 
D1S2800 D2S206 D9S286 D10S547 D11S935 D12S1617 D13S218 D14S65 
D1S2785 D2S338 D9S285 D10S1653 D11S905 D12S345 D13S263 D14S985 
D1S2842 D2S125 D9S157 D10S548 D11S4191 D12S85 D13S153 D14S292 
D1S2836 D9S171 D10S197 D11S987 D12S368 D13S156 
Ch 16 D9S161 D10S208 D11S1314 D12S83 D13S170 Ch 17 
Ch 15 D16S423 D9S1817 D10S196 D11S901 D12S326 D13S265 D17S849 
D15S128 D16S404 D9S283 D10S1652 D11S937 D12S351 D13S159 D17S831 
D15S1002 D16S2075 D9S287 D10S537 D11S4175 D12S346 D13S158 D17S938 
D15S165 D16S3103 D9S1690 D10S1686 D11S898 D12S78 D13S173 D17S1852 
D15S1007 D16S3046 D9S1677 D10S185 D11S908 D12S79 D13S217 D17S799 
D15S1012 D16S3068 D9S1776 D10S192 D11S925 D12S86 D13S285 D17S921 
D15S994 D16S3136 D9S1682 D10S597 D11S4151 D12S324 D17S1857 
D15S978 D16S415 D9S290 D10S1693 D11S1320 D12S1659 D17S798 
D15S117 D16S503 D9S164 D10S587 D11S968 D12S1723 D17S1868 
D15S153 D16S515 D9S1826 D10S217 D17S787 
D15S131 D16S516 D9S158 D10S1651 Ch22 D17S944 
D15S205 D16S3091 D10S212 D22S420 D17S949 
D15S127 D16S520 Ch 20 D22S539 D17S785 
D15S130 D20S117 Ch21 D22S315 D17S784 
D15S120 Ch19 D20S889 D21S1256 D22S280 D17S928 
D19S209 D20S115 D21S1914 D22S283 
Ch 18 D19S216 D20S186 D21S263 D22S423 
D18S59 D19S884 D20S112 D211252 D22S274 
D18S63 D19S221 D20S195 D21S266 
D18S452 D19S226 D20S107 
D18S464 D19S414 D20S119 
D18S53 D19S220 D20S178 
D18S478 D19S420 D20S196 
D18S1102 D19S902 D20S100 Ch: chromosome 
D18S474 D19S571 D20S173 Green: p arm 
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containing 2.5 pmoles of each primer with each primer being labeled by 
fluorescent dye, 0.2mM dNTP, 2.5mM MgCl!, 0.6 unit AmpliTaq Gold 
D N A polymerase, IX PCR buffer II (Perkin-Elmer, USA) and 60ng DNA. 
All primers were purchased from Perkin-Elmer. The PCR reactions were 
performed in an ABI PRISM 877 integrated thermal cycler. (Applied 
Biosystems, Foster City, CA). According to the manufacturer's 
recommendation the followings were the PCR conditions used. 15 mins at 
95followed by 10 cycles -composed of 15 sec at 94°C, 15sec at 55。C, 
and 30 sec at 72。C and then 22 cycles composed of 15 sec at 89°C, 15 sec at 
55°C, and 30 sec at 72°C. Amplified PCR products for multiple loci were 
pooled , mixed with ROX-labeled size standard (Genescan 400HD; Perkin-
Elmer) and electrophoresed in a 5% Long Ranger polyacrylamide/8M urea 
gel [ urea: 18.0g, Long Ranger Gel Solution (50%): 5.0ml, lOXTBE: 5.0ml, 
distilled water: to 50.0ml, 10% ammonium/per sulfate: 250|al, TEMED: 25)11； 
set up in an automated D N A sequencer (ABB77, Perkin-Elmer). 
IIL3.3 Pooling of PCR Products 
The PCR products of each primer from the same panel were pooled 
together with the following ratio: FAM: HEX: NED二 1:2:2. 3|il of loading 
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cocktail (2.5|il of deionized formamide, 0.5|LI1 of Genescan-400 H D (ROX) 
size standard) and 2|LI1 of each pooled PCR product were placed into a 
reaction tube. This mixture was denatured for 10 minutes at 95°C, and were 
immediately placed on ice. Three j^il mix was loaded into each well on a 
prewarmed (51°C ) 5% polyacrylamide gel. 
III. 3.4 Electrophoresis 
Gels were run for 2.5 hours at 200 watts, 60 mAmps, 3000 volts and 
was scanned at a rate of 2,400 scans/hour. These parameters are displayed in 
Section 4-18 and 3-7 for ABI PRISM GeneScan Analysis 2.1 (User's manual). 
While the samples were undergoing electrophoresis, the fluorescence was 
detected in the laser scanning region using filter set C, and data were collected, 
stored using the GeneScan Collection Software (Applied Biosystems). The 
fluorescent gel data collected during the run were analyzed using GeneScan 
Analysis Software 2.1 (Applied Biosystems) at the end of the run. Each 
fluorescent peak was quantitated in terms of allele, peak height, and peak area. 
The results were then imported into Genotyper 2.1 (Applied Biosystems) for 
further analysis and printing. The details about pattern for LOH, 
non-informative (NI) and retention (R) as well as calculation of L O H are 
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IIL3.5 Assessment of Loss of Heterozygosity by Calculating Allele Ratios 
Normal samples with two distinctly sized alleles at particular markers 
were termed "informative" (heterozygous). Those normal samples with 
only one allelic peak were termed non-informative (homozygous). For each 
informative locus of the tumor samples and their normal control, the allelic 
ratio (AR) was calculated (Figure 4). The A R was determined by measuring 
the peak height of the smaller allele (allele 1: Nl=normal; Tl=tumor) relative 
to that of the larger allele (allele 2: N2=normal; T2=tumor). The L O H value 
was defined as follows: L O H value 二 A R of normal/AR of tumor. The L O H 
values of < 0.70 or > 1.3 were considered to be indicative of LOH. The 
comparison of the allelic ratios between tumors and their controls was done 
using the formula N1 /T1 /N2/T2, where N1 and T1 were the height under peak 
of the smaller allele for the normal and tumor samples, respectively, and T2 
and N2 were the height under peak of the larger alleles. An allele scoring 
value >1.3 indicated that the tumor samples show L O H of the smaller allele 
whereas a value < 0.70 indicated that the tumor samples show L O H of the 
larger allele. The rules for data interpretation was also based on Jian et al 
(172). 
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IIL3.6 Standards of Evaluation 
The principles for the rules suggested by Jian et al (1999) were 
described as follows according to the original paper (172): 1. Comparative 
genomic hybridization or other independent methods (quantitative PCR, 
southern hybridization) need to be used in parallel with microsatellite analysis 
to exclude false interstitial deletion. Interstitial deletion is referred to non-
sequential deletion. Such a deletion is also termed "zebra pattern"; 2. During 
L O H analysis, it is very important to consider L allele (low molecular weight 
allele). This rule intensifies that the retention of markers should be evaluated 
with caution, particularly if they are associated with interstitial deletions. 
Only when retained marker is in the neighborhood of the L O H involving a L 
allele, the marker can be evaluated as significant. Otherwise, if no 
independent supportive data are available, the retained marker should be 
considered non-informative. Although these rules for LOH analysis relatively 
decrease the informativeness of microsatellite analysis, they increase the 
confidence in informative results and help to re-evaluate some conflicting 
data (172). So these rules can be considered as the gold standards for 
interpretation of LOH data, I think. 
III.3.7 Separating Allelic Loss From Allelic Duplication 
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Both allelic loss and gain can be exhibited as L O H pattern in 
microsatellite analysis. C G H was used to confirm whether the allelic 
imbalance refers to gain or loss. C G H analyses have been performed in all 
cases for the study. Those chromosomes that showed D N A gain as 
determined by C G H were excluded from the microsatellite analysis. 
IIL3.8 Statistical Analyses 
Fisher exact test and Mann-Whitney test were used for statistical 
analyses of the results (Tables 4-6). These parameters included the 
relationships between the tumor sites, patient age, sex, L O H specific sites and 
fractional allelic loss (FAL) values. 
Chapter IV. Results 
IV. 1 • Comparative Genomic Hybridization 
IV. 1.1. Overview 
In this study chromosomal imbalances in 28 primary ependymomas 
were analyzed by CGH. Results of the C G H analysis were summarized in 
Table 2 and an ideogram illustrating the regions and frequency of alterations 
is depicted in Figure 5. All tumors show multiple alterations involving entire 
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Table 4. Relation Between FAL Value and Tumor Sites 
No of Tumors 
Tumor Sites FAL<0.38 � FAL>0.38 P � 
IC � 5 4 0.999 
IS � 4 3 
�，Intracranial ;�，Intraspinal ;�，Fisher Exact Test, insignificant; 
�，Median FAL 
Table 5. Relation Between FAL Value and Patient Age 
No of Tumors 
Patient Age FAL<0.38(D FAL>0.38 P � 
Adult 5 6 0.308 
Children 4 1 
�，Median FAL;�，Fisher Exact Test, insignificant 
Table 6. Relation Between FAL Value and Patient Sex 
No of Tumors 
Patient Sex FAL<0.38 � FAL>0.38 P � 
Female 4 1 0.308 
Male 5 6 
� ,M e d i a n FAL;�，Fisher Exact Test, insignificant 
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Table 7. Association Between FAL and L O H at Specific Sites 
— 
Ch arms'  
LOH Median� Range Case No ？ 
^ + 044 0.13-0.72 n 0.792 
- 0.25 0.15-0.49 5 
16p + 0.41 0.15-0.72 12 0.441 
- 0.28 0.13-0.49 4 
16q + 0.48 0.15-0.72 9 0.07 
- 0.25 0.13-0.49 7 
17p + 0.49 0.21-0.72 9 0.878 
- 0.21 0.13-0.49 7 
19q + 0.43 0.13-0.72 9 0.91 
- 0.31 0.13-0.49 7 
20q + 0.43 0.13-0.72 10 0.428 
- 0.29 0.13-0.69 6 
22q + 0.43 0.13-0.72 10 0.878 
- 0-15-0.49 6 
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chromosomes or chromosomal arms. Figure 6 demonstrates a C G H profile of 
one representative case. The identified genomic imbalances, in order of 
decreasing frequency, were loss of chromosomes 22q (71%), 16 (57%), 17 
(46%), 6 (39%), 19q (32%), 20q (32%) and gain of chromosomes 5q (46%),, 
12q (39%)，7q (36%), 9q (36%) and 4q (32%). 
IV. 1.2. Common deletion regions 
The most frequent altered chromosome was 22q with a frequency of 
loss 71% (20/28). Of these 20 cases, 17 of them displayed complete loss of 
22q while 3 tumors (Cases 3, 7, 21) exhibited partial 22q loss with 
breakpoints determined at ql2-qter and ql3-qter. A common deletion region 
was identified at the 22ql3-qter. 
A high incidence of D N A loss of chromosome 16 was found in 16/28 
(57%) tumors. Five cases showed complete loss of chromosome 16 and 
eleven samples demonstrated partial loss with the majority of them having 
deletion in both or either distal ends of chromosome 16. Two overlapping 
deletion regions were identified at 16pl3.1-13.3 and 16q22-24. 
Loss of chromosome 17 was detected in 13/28 (46%) ependymomas. 
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partial loss of 17. No overlapping regions of loss could be determined on 
chromosome 17. 
Other frequently affected chromosomes with D N A loss were 6 (36%), 
19 (32%), 20 (32%). No common region of loss was identified on 
chromosome 6, whereas overlapped deletion regions on chromosomes 19 
and 20 were localized to 19ql3.1-13.4 and 20ql3.1-13.2, respectively. 
IV. 1.3. Common duplication regions 
Overrepresentation of genetic material was commonly detected on 
chromosomes 5 (13/28, 46%), 12 (11/28, 39%), 7 and 9 each at (10/28, 36%) 
and 4 (9/28, 32%), with overlapped regions of gain mapped to 5q21-22, 
12ql5-24.1, 7ql 1.2-31.2, 9ql2-32 and 4q 23-28 respectively. Interestingly, 
D N A gains of chromosomes 4q, 5q, 7q, 9q and 12q were found 
predominantly in the adult series. The gains of chromosomes 4q and 5q were 
very rarely reported in ependymomas (116, 122, 127). No frequent 
concomitant loss of chromosome 10 and gain of chromosome 7 were found. 
IV.2. High-Resolution Allelotyping (Microsatellite Analysis) 
IV.2.1 • Overview of Results 
Sixteen cases were investigated for the allelic status using a panel of 
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382 microsatellite marker mapping to 22 autosomes. The average interval of 
markers was about lOcM. All 39 nonacrocentric chromosomal arms were 
assessed. An average of 70% informative loci per case was detected in these 
tumors. The informativeness is similar to the average heterozygosities 
(60-90%) distributed in human genome (38). All nonacrocentric 
chromosomal arms were informative for all tumors in this high-resolution 
allelotype analysis. In the current study, contents of the neoplastic cells were 
at least 80% in each sample after histologic verification. Representative 
examples of L O H are shown in Figures 7-1 to -6. 
Allelic imbalance of each locus was scored according to the defined 
criteria mentioned in the Material and Method Section. Fractional allelic 
loss (FAL) of a tumor is defined as the number of chromosomal arms on 
which allelic loss/allelic imbalance is observed, divided by the number of 
chromosomal arms for which polymorphic markers are informative (20). 
Allelic imbalance (Al) is includes allelic loss (AL) and allelic duplication 
(AD). Other genetic method such as C G H can complement allelotyping in 
distinguishing allelic loss from allelic duplication. 
In the current study, C G H experiment separated Al from AL. 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































- Zheng PP 69 
loss on the designated chromosomal arms in the informative cases in graphic 
form. Figure 9 illustrates the overall status of 16 ependymomas as regards 
to proportion of L O H at each chromosome arm, as a percentage of 
informative cases as well as fractional allelic loss. Figures 10-1 to 10-22 
shows results of microsatellite analysis on individual chromosome in 16 
ependymomas. 
Individual FAL values ranged from 0.10-0.69 and the mean FAL was 
0.38 in the current study. No association between FAL value and age, sex 
and location was found (Table 4-6). The possible association between FAL 
values and L O H specific sites also was investigated. Results for the 9 
chromosomal arms with highest frequencies of L O H are shown in Table 7. 
No association was found for the 9 most frequent sites of loss. 
Microsatellite instability (MSI) was observed in 6/16 cases (37.5%). 
Tumors that demonstrate different sizes of alleles as compared with their 
respective normal sample are scored as MSI. This is usually indicated by a 
clear peak shift or by the presence of extra peaks in the tumor sample as 
compared with the normal allele sample. The number of loci with 
microsatellite instability in these tumors ranged from 1 to 4, suggesting that 
the frequency of MSI for each case is rather low. No clear specific 
- Zheng PP 70 
Chromosomal 
Arms 18 26 22 12 28 21 9 5 10 19 25 8 13 6 11 7 LOH% 
I p I I I I I I I I 1 WM M ^ ^ 31.3 
IQ — 门 • 一 I I 6.3 
2p Z Z ^ ^ ^ H 31.3 
2q 18.8 
Z Z J U Z Z I Z I ^ H Z Z H ^ I ^ H ^ ^ ^ ^ I 43.8 
Z Z P H Z Z ^ ^ ^ ^ ^ ^ P ^ P H 37.5 
4p 18.8 
4q m M 25 
5p 18.8 
5q ^ ^ ^ "••ZZ I I I ^ ^ ^ H " . " 12.5 
43.8 
6q I I Z H H I Z I I H ^ I - I Z p H H ^ l ^ H H I I Z p i i ^ ^ ^ ^ ^ l ^ ^ H 68.8 
7p 18.8 
7q ^ ^ ^ 18.8 
8p Z Z H B Z Z 43.8 
ZZBBIILZZ Z Z ^ ^ ^ H ^ K Z Z B ^ B B Z Z I 31.3 
9q H z Z Z Z Z Z Z Z ~ ~ 3 1 . 3 
lOp Z Z M B Z H Z Z ^ ^ ^ H I ^ Z Z S ^ ^ H 31.3 
loq ZZIHBZZ] 43.8 
lip 37.5 
i i q ^ ^ ^ H j l ^ P ^ ^ H ^ ^ ^ H 37.5 
i2p W —m^M 31.3 
12q ^ I I 18.8 
13q I I n — p a P ^ B B ^ 43.8 
i4q Z Z B B Z Z Z Z i B L I I Z Z ^ H ^ ^ ^ ^ ^ ^ ^ H ^ I 43.8 
E 2 
i7p 56.3 
i7q ！ • 一 5 0 
18p Z Z ^ ^ ^ J 6.3 
18q ^ ^ 18.8 
i9p Z Z H E I Z P ^ ^ B Z Z B I ^ B H Z Z 56.3 
19q 56.3 
20p I I ^ — ^ ^m 56.3 
21q 31.3 
22q B B 62.5 
0.1 0.13 0.13 0.21 0.21 0.23 0.23 0.26 0.26 0.44 0.49 0.49 0.67 0.67 0.69 0.69 
Fractional Allelic Loss (FAL) 
Fig 9. Overall LOH status of 16 ependymomas. Black box, allelic loss; open box, retained heterozygous 
alleles. The arm colum designates the 39 nonacrocentric arms examined. The LOH colum displays the 
rates of LOH at each chromosomal arm as percentage of informative cases. LOH, loss of heterozygosity. 
Case numbers are shown on the top. The FAL value of each tumor is shown in the bottom of each colum. 
Mean FAL=0.38. 53.5% (mean percentage of LOH + standard deviation: 36.7% + 16.8%) is chosen to be 
as a cutoff. This cutoff represents the 99% confidence upper limit for the overall rate of random chromosom 
losses in the study. Those amplified chromosomal arms indicated by CGH are excluded from the analysis of 
FAL. 
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- Zheng PP 93 
susceptible site was identified. Figure 11 shows one representative MSI. 
A lot of chromosomal breakpoints of L O H could be identified in 
this study. Some of this could not be localized definitely because of 
non-informative markers that lay between regions of loss and retained 
markers. If a relatively high number of breakpoints are found in a region, this 
could be suggestive of a structural feature e.g. a fragile" site or “ hotspot (36). 
IV.2.2. LOH Profile of Individual Chromosome 
Frequency of L O H for individual chromosomal arm varied from 
6.3% (Iq and 18p) to 75% (16p). The mean percentages of L O H was 36.7%. 
In the present study, 53.5% (Figure 8) was chosen to be a significant 
percentage of L O H which represents the 99% confidence upper limit for the 
overall rate of random chromosome loss in chromosomes 6q (68.8%), 16p 
(75%), 16q (56.3%), 17p (56.3%), 19p(56.3%), 19q (56.3%), 20 (56.3%), 
20q (56.3%), 22q (62.5%). Among these chromosome arms, the remarkably 
high frequency of LOH on 16p (75%) and 22q (62.5%) indicated that such 
alterations possibly played a critical role in the development of ependymoma. 
Gains of chromosomes 4q, 5q and losses of chromosomes 16p, 16q, 19q, 20q 
as frequent chromosomal alterations in the current study have not been 
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- Zheng PP 95 
characterized in previous studies for ependymoma. In this study, no 
significant association of fractional allelic loss (FAL) with patient age, sex, 
site could be found. The correlation of FAL and specific chromosomal sites 
was also statistically insignificant. 
IV.2.3. Overlapping Small Deletion Regions 
In this high-resolution allelotyping, several overlapping small deletion 
regions (OSDRs) on the chromosomal arms have been defined (Table 8). 
Figures 10-6，-16,-17,-19, -20, -22) marked these delineated OSDRs, which 
were deduced by tumors containing deletions on these chromosomal arms. 
The size of the mapped loci on several chromosomal regions was from 6.3 to 
29.9cM. Principles for define a SDR and L O H frequency are listed as follows: 
1. Determining the target arms that smaller deletion regions (SDRs) are 
possibly located according to the cutoff (Figure 8), that is: Localizing a SDR 
should be performed in the arms above the cutoff ； 2. Informative cases should 
occupy at least 50% of totally examined cases. In these informative cases, the 
deleted cases also should occupy at least 50%; 3. For flanking markers in a 
SDR, if these markers about their informativeness and/or frequency of 
deletion are close to 50%, they can be incorporated into the SDR; 4. Using 
- Zheng PP 96 
Table 8. Overlapping Small Duplication and Deletion Regions  
Chromosome Duplications* Deletions* Markers  
4q 4q23-28 
5q 5q21-22 
7q 7ql 1.2-31.2 
9q 9ql2-32  
12ql5-24.1  
6q 6q24-qter D6S264 
D6S446 
D6S281 
16p 16pl2-13.1 D16S3046 
D16S3103 
16q 16q21-22 D16S515 
D16S516 
17p 17pl3 D17S849 
Dr7S831 
19q 19qll-13.3 D19S414 
D19S220 
20q 20ql3.1-13.3 D20S100 
D20S196 
22q 22ql3.1-13.3 D22S423 
D22S274  
*, CGH data; #, Allelotyping data 
- Zheng PP 97 
retention marker (s) to demarcate the upper and low boundary of a SDR; 5. 
L O H frequency refers to the following: For each marker, the number of L O H 
cases is divided by the number of informative cases. One OSDR was mapped 
at chromosome 6q24-qter (between D6S158land telomere). The frequency 
of L O H in this region was 75% of informative cases. On chromosome 16 
there were two OSDRs being mapped to 16pl2-13.1 (between D16S3075 and 
D16S3068) and 16q21-22 (between D16S503 and D16S3091). The 
frequencies of L O H in the two regions were 75% and 50% informative cases 
respectively. One OSDR was mapped tol7pl3 (between telomere and 
D17S938). The frequencies of L O H in the region was 54% of informative 
cases. There was one OSDR, locating in the chromosome 19ql 1-13.3 
(between D19S221 and D19S420). In the regions, the frequency of L O H was 
50% of informative cases. One OSDR was mapped to 20ql3.1-13.3 
(between D20S178 and D20S173). The frequency of L O H in this region was 
64% of informative cases. Finally one distinct OSDR was defined on the 
chromosome 22q, which was located at 22ql3.1-13.3 between D22S283 and 
telomere. In this region, the frequency of LOH was 70% of informative 
cases. 
Chapter V. Discussion 
- Zheng PP 98 
V. 1. General Outline 
This is the first study to combine C G H and high-density fluorescent 
microsatellite assay of ependymomas. Most of the previous genetic studies 
for ependymomas were limited to cytogenetic analysis (61, 119, 120, 131) 
and small panels of markers for L O H study (134, 136, 146, 147, 162, 173, 
174). The number of genomic imbalances reported in these studies were 
much lower than that of the current study. M y results showed that the 
sensitivity of genomic duplication/LOH study was increased greatly by 
combining C G H and high-resolution allelotying with a large battery of 
microsatellite markers. In addition, my results also confirmed most of the 
genetic alterations reported in previous studies. More important, high 
frequencies of deletions on chromosome 16p (75%), and significant 
duplication on chromosome 5 (46%) were also found, which were not 
reported in previous studies of ependymomas. 
Sixteen cases of ependymomas have been subjected to both C G H and 
allelotyping analyses. The results obtained from these two analyses were 
concordant. Figure 8 shows the frequency of L O H for each chromosomal 
arm. Significant allelic losses above the cut-off level (53.5%) were found in 
chromosomes 6q, 16p, 16q, 17p, 19p, 19q, 20p, 20q and 22q, suggesting the 
- Zheng PP 99 
involvement of multiple tumor suppressor genes in the tumorigenesis of 
ependymomas. The combined study gave a comprehensive picture of the 
allelic duplication/loss for the 22 autosomes, which has exhibited the 
involvement of non-random chromosome abnormalities on 4q，5q, 6q, 7q, 9q， 
12q, 16,17,19，20,22q in ependymoma tumorigenesis by possible synergistic 
or independent actions. 
Frequent chromosomal alterations have been detected in chromosomes 6, 
17 and 22q (1,3, 120, 123, 124) and less frequently reported chromosomes 
were chromosomes 7, 9 and 12 documented in karyotypes of 125 
ependymoma review (120). In addition, new loci such as 4q, 5q, 16, 19 and 
20 were found in this study which may be associated with ependymoma 
tumorigenesis. The present data confirmed these results as well as 
identifying several regions previously unknown or uncertain to be involved in 
ependymoma carcinogenesis. Several putative TSG or oncogenes on 
chromosomes 4q, 5q, 16, 17, 19, 20, 22q emerge as interesting novel 
candidate genes for a initiation or progression associated in ependymomas. 
V.2. Chromosome 22 
A distinct overlapping region of deletion on chromosome 22 was 
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defined, specifically on 22ql3.1-13.3 with a genetic distance of 
approximately 7.8cM. This deletion region was distinctly separate from the 
NF2 gene locus (22ql2). Since chromosomal translocation may also be 
revealed as L O H (168), whether this region represents a translocation 
breakpoint cannot be excluded. Alterations of this region have been 
demonstrated in several ependymomas as a breakpoint or fragile site (136, 
137). In these reports, the region of deletion at 22q was far from NF2 gene 
(136, 137). 
In the current study, there were two adult intraspinal cord 
ependymomas (Cases 5，10), and one adult (Case 11) and one pediatric (Case 
25) intracranial ependymomas in which the deletion regions involved 
22ql 1.2. This region harbors the hSNF5/INIl tumor suppressor gene, which 
i 
encodes a member of the chromatin-remoldelling SWI/SNF multiprotein 
complexes (51, 150-153). The putative tumor suppressor gene hSNF5/INIl, 
showing homozygous deletions and truncating mutations in malignant 
rhabdoid tumor, has been identified in 22qll.2 (154). The finding in the 
current study supports the hypothesis that a second TSG is present on 
chromosome 22 at least in some intraspinal and intracranial ependymomas, 
possibly predominantly in adult cases. Another interesting finding was that 
there were three adult intraspinal cases (Cases 5, 9, 10) and one pediatric 
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intracranial case (Case 25) whose deletion regions on chromosome 22 
spanned the NF2 region (22ql2). These findings seem to support the recent 
finding that mutation of NF2 is specifically associated with W H O grade II 
ependymomas that have a spinal localization (50), and also indicated the 
involved candidate gene for the intraspinal ependymoma may overlap other 
genes from NF2. 
Chromosome 22 abnormalities (i.e., monosomy 22 or 22q) have been 
singled out in previous discussions of karyotype and L O H studies in 
ependymomas (134-136,147,156，157, 162). A numerical abnormality of 22 
or breakpoint 22ql 1-13，resulting in complete or partial monosomy 22, was 
seen in 56% adult and 31% pediatric tumors (120). About 2-5% of 
ependymomas with neurofibromatosis type 2 (NF2) were observed (143). 
Also there were some reports about ependymomas supporting NF2 tumor 
suppressor gene located at 22ql2 (50, 135, 144, 145). However, at least two 
studies found a different locus to be involved in ependymoma tumorigenesis 
(134, 146). It possibly indicates that another TSG (s) resided at 22q are 
involved in the tumori genesis of ependymomas other than NF2. The 
putative tumor suppressor gene hSNF5/INIl on chromosome 22q may be 
possibly a responsible gene in the tumorigenesis of ependymoma. 
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Deletion of chromosome 22q (137, 155, 157，173，174), or evidence 
of L O H of 22q (48，123) has also been implicated in a variety of brain tumors 
(eg, meningiomas, sporadic astrocytoma, and acoustic neuroma). However 
mutation of NF2 was infrequently found in meningioma and astrocytomas 
(175). Moreover, loss of genetic information on chromosome 22 is also 
common in several extracranial tumors, including rectal carcinoma (176), 
methothelioma (177), and peripheral benign schwannomas (178). In order to 
clarify the target gene(s) involved in ependymoma tumorigenesis, a large 
number of cases will need to be studied for a detailed deletion mapping. 
Analyzing more samples and using more markers will open a way to narrow 
down the region where TSGs may be localized. The current data indicate 
that at least two TSGs on chromosome 22q are involved in the development of 
ependymoma. In addition, the breakpoints on the remaining chromosome 22 
in some intracranial and intraspinal ependymomas suggests other potential 
tumor suppressor loci involved in ependymomas. 
V.3. Chromosome 17 
Frequent loss or deletion of chromosome 17 in ependymomas has been 
reported in many previous studies (119, 124, 129, 148, 159). A well-known 
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tumor suppressor genep53 is located at chromosome 17pl3.1 region. 
However,mutation was only occasionally reported in ependymoma (148, 
158-161). In the 5 reports, the cases of the detected p53 mutation were 1/18, 
3/26, 1/6, 0/15, 1/31 respectively (146, 158-161). In one of these studies, 
microsatellite analysis study done by von Haken et al (1996), 50% 
ependymoma sample harbored 17p arm loss, preferentially being distal to the 
p53 locus (146). These findings suggest that in contrast to many other 
human cancers, p53 mutation is not important in the tumorigenesis or 
progression of ependymomas. However, occasionally germ line mutation of 
p53 was reported in individual intracranial ependymoma (162). 
The current C G H data indicated D N A losses in both arms of 
chromosome 17. The allelotyping data further narrowed down these deleted 
regions. One O SDR was mapped to 17pl 3. The frequency of L O H in this 
region reached 54% of informative cases. Since p53 mutation is rare in 
ependymomas, other unknown TSG (s) is/are possibly covered in this region 
and involved in the development of ependymomas. Deletions involving 17q 
23 have been reported in ependymoma (129, 156). No OSDR in 
chromosome 17q can be defined in this study. 
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V.4. Chromosome 6 
Loss of chromosome 6 has been reported to be a common genetic 
aberration in pediatric ependymomas (1,162). Of the three studies (1,2,162), 
loss of chromosome 6 was detected in 3 of 4 cases, 4 of 13 cases, 5 of 23 
cases respectively. However other studies showed loss of chromosome 6 
occurred at similar frequencies in pediatric and adult patients (124-126, 156). 
The current C G H data exhibited frequent deletion of chromosome 6 in adult 
ependymomas. In contrast, only a single childhood ependympma in this 
series displayed chromosome loss, but this might be due to the very limited 
pediatric cases studied. Using allelotyping, the general frequency of L O H for 
chromosome 6q was as high as 50% of informative cases. One OSDR was 
defined at chromosome 6q24-qter. The frequency of L O H in this region 
reached 75% of informative cases. 
Recently human AF-6 tumor suppressor gene was found to be located 
in 6q27 (179, 180). The AF-6 gene product is implicated as a putative 
target of RAS, since the protein contained a RAS interacting domain (181, 
182). The AF-6 protein is considered to play a regulatory role in cell-cell 
adhesion via a signal transduction pathway downstream to RAS. AF-6 gene 
was originally found in the form of a chimeric gene with the acute 
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lymphoblastic leukemia gene (ALL-1) at a locus in the t(6;l I)(q27;q23) of 
acute myloid leukemia (183). The defined OSDR in the current data was 
within in AF-6 gene locus. Chromosome 6 loss has also been detected in 
primitive neuroectodermal tumors, non-Hodgkin's lymphoma, carcinomas of 
prostate, hepatocellular carcinoma, ovary, leukemia, Burkitt's lymphoma 
(184-195). The candidate TSG on 6q27 perhaps is involved in the 
tumorigenesis of ependymomas as well as other cancers. 
F.5. Chromosome 16 
Loss of chromosome 16 was not reported as a recurring markers in 
ependymomas. Only a few ependymomas were shown to be deficient in 
chromosome 16. Of these reports, loss of chromosome 16 was detected in 
1 of 5 cases, 2 of 6 cases, 1 of 12 cases, 1 of 23 cases, 1 of 13 cases, 1 of 4 
cases, 1 of 2 cases, 1 of 1 cases (1，3, 124, 126, 131，156, 196, 197). 
However, in this study a high frequency of monosomy or deletion for 
chromosome 16 was found. Two overlapping small deletion regions 
(OSDRs) on p and q arms were mapped respectively. One OSDR was 
demarcated at 16pl2-13.1, which overlapped one candidate TSG 
(TSC2/PKD1) gene region (16pl3). LOH of the region was present in 9 of 12 
(75%) informative cases. A high frequency of LOH at this region was rarely 
reported and only one paper described LOH of this region in a breast tumor 
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(198). These findings suggest that chromosome 16p contains a tumor 
suppressor gene that is possibly involved in the development of ependymoma 
and a subset of breast cancer. 
Another OSDR on chromosome 16 was mapped to 16q21-22, which 
harbor the E-Cadherin (CDHl) gene at the 16q22. L O H of the region was 
found in 55% of the informative cases. This gene encodes a cell adhesion 
molecule associated with tumor invasiveness and metastasis. Studies have 
implicated regions on chromosome 16q in which L O H was associated with 
various neoplasia (199), such as primitive neuroectodermal tumors and 
medulloblastomas, as well as in cancers of other organs such as breast, Wilms 
tumor, myeloid malignancy, prostate, lung (184,200,201, 202). L O H for the 
cell adhesion molecule E-caderin gene (CDHl) has been implicated in the 
development of primary epithelial neoplasias (202). 
Recently, Filippova et al (199) identified a novel TSG, c-myc 
transcription factor (CTCF), from the 16q22.1 region. The CTCF gene 
encodes a DNA-binding nuclear protein that has been shown to be a 
transcriptional repressor of the M Y C oncogene (199). Overexpression of 
M Y C is commonly found in many human cancers. Hence it is tempting to 
speculate that LOH for the CTCF locus at 16q22.1 may result in upregulation 
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of MYC. Monosomy 16 generally had a poor prognosis in myeloid 
malignancy and gastroesophageal adenocarcinoma (201). In a recent report, 
3/3 cases of low grade ependymomas showed losses of 16q (203). Therefore, 
the clinical significance for loss of 16 in tumors is disputable. A larger study 
with monosomy 16 is necessary t o determine more accurately the clinical 
course and prognosis. In the current study five cases showed monosomy 16. 
It remains to be seen whether the candidate tumor suppressor gene(s) on 16q 
also may be operative in the development of these tumors including 
ependymomas. 
V.6. Chromosome 19 
Loss or deletion of chromosome 19 was frequently detected in the 
current study, but only individual case was reported in previous metaphase 
cytogenetic study for ependymoma (204). There was one OSDR on 
the chromosome 19, locating at 19ql 1-13.3 (between D19S221and 
D19S420). In these regions, the frequencies of L O H 50% of informative 
cases respectively in this study. One known TSG found on 19q 13.2 is LKB1 
(14, 129, 205-207). The defined OSDR was included in this gene 
region, suggesting the TSG perhaps play a role in the tumorigenesis of 
ependymomas. 
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Loss or deletion of chromosome 19 was also frequently found in 
other glioma subtypes, predominantly in oligodendroglioma (49, 168, 205, 
208-216), Ritland et al evaluated 100 brain tumors for L O H analyses and 
further indicated region-specific L O H on chromosome 19, and concluded loss 
of 19q and retention 19p are strongly associated with oligodendroglioma and 
mixed oligodendroglioma and astrocytoma (MOA), whereas loss of 19p and 
retention of distal 19q is associated with astrocytoma (213). 
V.7. Chromosome 20 
Loss or deletion of chromosome 20 was frequently detected in 
leukemia (217-225), and very rarely reported in cytogenetic metaphase study 
for ependymoma (195). Only individual case was reported (195). However, 
in the current data, loss of chromosomes 20p and 20q showed the same L O H 
frequency ( 56.3%). One OSDR was mapped to 20ql3.1-13.3. K R M L 
(MAFB) tumor suppressor gene was resided at 20ql 1.2-13.1 region (218). 
The defined OSDR was within the gene region. This gene plays a pivotal 
role in regulating lineage-specific hematopoiesis by repressing ETSl-
mediated transcription of erythroid-specific genes in myeloid cells (218). 
It remains to be determined whether K R M L is involved in the tumorigenesis 
of ependymomas. 
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V.8. Chromosome 7 
D N A gains in chromosome 7 was frequently reported in other gliomas 
(51, 125, 173，226-234), especially 7pl2-13 and 7q31 regions，but was 
far less commonly encountered in ependymomas (119, 120). In the 158 
cytogenetic analyzed ependymomas, there were about 18 cases (11%) 
showing gain of chromosome 7(119, 120). In the current C G H data, 
duplication of chromosome 7 was detected in 36% cases. The defined 
common duplication region was mapped to7ql 1.2-31.2. This region covered 
the loci ofERBBI (7pl2.1) and EGFR (7pl2.3). 
In the two C G H studies, one for high-grade astrocytic tumors and 
the other for low-grade astrocytic tumors, the most consistent finding was a 
gain of chromosome 7 in both tumor groups (8/9 versus 5/10) (287, 233). 
Regarding the data, the authors concluded that the increased expression of 
genes on chromosome 7 provided an important growth advantage to glial cells 
that is followed by additional changes, e.g., the loss of putative TSGs on 
chromosome 10, which is almost invariably lost in glioblastomas (233). 
In GBM, gain of chromosome 7 always occurred concurrently with the 
loss of chromosome 10 (48). However, some low-grade astrocytic tumors 
often showed gains of chromosome 7 without concomitant loss of 
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chromosome 10 (232). Interestingly, also no frequently concomitant gain 
of chromosome 7 and loss of chromosome 10 were detected in my C G H data. 
The finding perhaps indicates ependymomas are genetically distinct from 
GBM. 
The biological significance (indicating aggressive behavior or not) of 
a gain of chromosome 7 in tumors is disputed in the scientific literature (235). 
Trisomy 7 and alteration of the 7q-arm are also frequently detected in other 
malignant tumors (236-241). Medullablastomas, adult low-grade astrocytoc 
tumors, choricarcinomas and endocrine pancreatic tumors have also been 
reported to harbor 7q gain (202, 233, 235). 
V.9. Chromosome 12 
Gain of chromosome 12 was infrequently detected in ependymomas 
(119, 120). Of the 158 cytogenetic analyzed ependymomas, gain of 
chromosome 12 was detected in 10/158 (8%)(119, 120). Gain of 
chromosome 12 found in cases 39% in the current C G H data. An 
overlapping small duplication region (OSDR) was located at 12ql5-24.1. 
Several oncogenes such as WNTl/INTl，OS9, GLI，SAS/CDK4, MDM2 are 
present in 12q. MDM2 is mapped at 12ql4.3-ql5. The defined OSDR was 
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included in this region. Gain of chromosome 12 is usually associated with 
poor outcome in prolactinoma subtype of pituitary adenomas (242). 
Amplification of M D M 2 on chromosome 12 has been implicated in some 
ependymomas (158, 243). However the results seemed to conflict between 
the two studies (158,243). One study showed rarely M D M 2 amplification in 
ependymomas (1/26) (158), whereas data from another study showed 
that M D M 2 amplification and overexpression was detected in 35% samples 
(243). The recent study appears to greatly support that M D M 2 gene 
amplification possibly play a role in the tumorigenesis of a subset of 
ependymomas. 
V.IO. Chromosome 9 
In the 158 analyzed ependymomas, gain of chromosome 9 was detected 
in 13/158 (8%) (119, 120). In the current C G H data, the frequency of D N A 
duplication on chromosome 9 was 36%. Small overlapping region was 
delineated at 9ql2-32. Unfortunately, there is no known oncogene reported in 
this region. However at chromosome 9q34.1 locus, an oncogene 
ABLl 1/ABL is located. Gain of chromosome 9 was also reported in other 
diseases and tumors such as adenocortical carcinoma (244), and 
polycythaemia vera (245). The significance of chromosome 9 gain in the 
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ependymoma awaits further clarification. 
V.l l . Chromosome 5 
Gains of chromosome 5q is a major finding in my C G H data (46%), 
which has been very rarely reported in previous cyotgenetic studies for 
ependymomas. Only two cases were reported (119, 125). The overlapping 
small duplication region was delineated at 5q21-22. The duplication of this 
region was frequently reported in renal cell carcinoma, bladder carcinoma and 
thyroid neoplasm (246, 247). No candidate oncogenes have been identified 
in this region. 
V.12. Chromosome 4 
Gain of chromosome 4 was also very rarely reported in the previous 
cytogenetic study. Only one case was reported by Rey et al (130). Gain of 
chromosome 4 was detected in 32% cases in the current C G H data. 
Overlapping small duplication region was defined at the 4q 23-28. This 
region was within the epidermal growth factor locus (4q24-26). Recently, 
gain of chromosome 4 was reported in human G B M and the experimental 
gliomas of the rat by C G H (248, 249). 
V.13. Correlation of CGH with Allelotyping in the Study 
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The results from C G H and allelotyping were generally consistent with 
each other. Both data showed parallel overview of deletions in all the 
frequently or significantly affected chromosomes/chromosomal arms, 
including chromosomes 6, 16，17, 19，20, 22, and similar small deletion 
regions. However, there also were some discordant regions owing to the 
inherent limitations about the two techniques, such as in case 25 for 
chromosome 11, C G H did not detect loss of the chromosome, while 
allelotyping showed multiple deletion regions. In case 8 for chromosome 6, 
C G H displayed whole chromosome loss, whereas allelotyping demonstrated 
most of regions were covered by non-informative markers. The discrepancy 
may be due to the following reasons: 1. C G H has limited sensitivity and 
resolution (see Section Lll). 2. It could in part result from the poor sensitivity 
of C G H in analyzing chromosomes near the centromere (pericentromeric and 
paracentromeric regions), where some of the microsatellite markers mapped. 
These regions are usually blocked by unlabelled Cot- D N A in various extent 
(234). In addition, telomeric regions are also unreliable in C G H data. As the 
fluorescence intensities decrease towards the telomere, they will begin to 
approach the background fluorescence (234). 3. C G H and allelotyping 
analyses have different measuring ways about abnormalities (166). 
So-called "different measuring ways" actually involve some mechanisms 
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about allelic imbalances, which are summarized as follows: Mechanisms of 
subchromosomal allelic imbalance include deletion, duplication, mitotic 
recombination, nondisjunctional chromosome gain, nondisjunctional 
chromosome loss with or without redupliction, locus-restricted events such as 
gene conversion or point mutation, and epigenetic allelic inactivation (166). 
In a locus that becomes homozygous with reduplication, mitotic 
recombination allelic imbalance analysis would detect this result whereas 
C G H would not. Similarly, in an aneuploid tumor, C G H may score a gain or 
loss that restore the ratio of maternal to paternal alleles in that region, so no 
allelic imbalance would be seen (166); 4. High frequency of non-informative 
markers cover the region (s) concerned (164). Case 8 was a typical example 
for the status. This case covered a high ratio of non-informative markers. 
However, this is inevitable before doing the experiment. 
V. 14. Conclusion 
In conclusion, in the current study, an overview on the aberrations of 22 
autosomes has been analyzed by C G H (28 cases) and high-density 
allelotyping (16 cases). Some chromosomal aberration associated with the 
development of ependymomas have been identified. These findings suggest 
a greater degree of genomic duplication and loss in ependymomas than has 
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been recognized previously and highlight chromosomal loci likely to contain 
oncogenes or tumor suppressor genes that may contribute to the molecular 
tumorigenesis of this tumor. The detected novel regions also open the doors 
for further studies such as narrowing down these loci, explore or examine the 
candidate gene(s) in future. Also the advantages of the combining methods 
were "seen" in this study. Hopefully elucidating the genetic events 
underlying the formation of ependymomas, which would hint for 
improvement in diagnosis, treatment and prognosis of ependymomas. 
Chapter VI. Limitations of the Study 
Each study has its limitation(s) in different degrees. The limitations of 
this study are listed below: 
1。The number of cases was relatively small, particularly for allelotyping 
analysis. The generated differences did not reach statistical significance due 
to the limited case numbers. 
2. Recent L O H sensitivity study indicated there is a systemic difference 
between the low (L) and high (H) molecular weight alleles of the same 
marker according to a developed allelic titration assay (ATA) (164, 172). 
The study concluded the assay sensitivity depend on which allele (H or L) is 
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deleted for same marker and same tumor in the presence of contaminating 
normal cells. That is: Loss of H alleles is much more easily detected than loss 
of L ones. Alimov et al randomly screened 100 papers published between 
1994 and 1999. These papers revealed that the loss of L allele was detected 
only at 52% frequency of the loss of H allele (164) and the results were 
statistically significant. These results suggest that about 50% of the L allele 
deletions in tumor samples may go undetected (164). Thus, although the 
used samples in my study contained at least 80% of tumor cells which were 
verified histologically, yet minor normal tissue contamination such as blood 
vessel, reactive cells were inevitable. A contamination of such a degree will 
possibly affect low molecular allele detection to a certain degree. 
Chapter VII. Future Study 
The future study should focus on the vertical depth and horizontal 
width. The details are listed as below: 
1. Case number needs to be increased to be studied. Again a parallel study 
of C G H and allelotyping analysis for equal case number is best as the result 
produced from the two different techniques for same cases will more 
elaborate than single technique. 
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2. SSCP-DNA sequence analysis，FISH or microarray C G H techniques 
should be included in the future studies. These techniques will aid in the 
future study more elaborating. SSCP is necessary to confirm the mutated 
gene which may indicate loss of a tumor suppressor gene. FISH or 
microarray C G H can confirm the detected gain or amplification of specific 
genes or regions by the conventional CGH. In addition, FISH may also 
narrow down the regions of involvement indicated by CGH, and pinpoint 
specific genes in cancer development. 
3. Microdissection is suggested to be performed in the future studies. It can 
Minimiz normal tissue contamination to the least degree and greatly increase 
the precision for data interpretation. 
The End 
8/2000 
- Zheng PP 118 
References 
1. Reardon DA, Entrekin RE, Sublett J, Ragsdale S, Li H, Boyett J, 
Kepner JL, Look A T (1999): Chromosome arm 6q loss is the most 
common recurrent autosomal alteration detected in primary 
pediatric ependymoma. Gene Chromosomes Cancer 24: 230-237. 
2. Hirose Y, Kundar S, Bollen A W , Berger MS, Feuerstein B G 
(1999): Chromsomal abnormalities in ependymomas detected by 
comparative genomic hybridization. Proceeding of the American 
Association for Cancer Research 40: 537 (Abstract No.: #3540). 
3. Blacker H，Rasheed BK, McLendon RE, Friedman HS，Batra SK, 
Fuchs HE, Bigner SH (1996): Microsatellite analysis of childhood 
brain tumors. Genes Chromosomes Cancer 15: 54-63. 
4. von Deimling, Fimmers R, Schmidt MC, Bender B, Fassbender F, 
Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D, 
Steinbeck S, Wick W, Flatten M, Muller DJ, Przkora R, Waha A, 
Blumcke B, Wellenreuther R, Meyer-Puttlitz B, Schmidt O, 
Mollenhauer J, Poustka A, Stangl AP, Lenartz D, von Ammon K 
(2000): Comprehensive allelotype aand genetic analysis of 466 
human nervous system tumor. J Neuropathol Exp Neurol 59: 544-
558. 
- Zheng PP 19 
5. Louis D N and Gusella JF (1995): A tiger behind many doors: 
multiple genomic pathways to malignant glioma. Trends Genet 11: 
412-415. 
6. Varmus H. In: R. Weinberg (ed) (1989): Oncogenes and molecular 
origins of cancer, Cold Spring Harbor, NY: Cold Spring Harbor 
Laboratory, pp 3-44. 
7. Fearon ER, Volgelstein B (1990): A genetic model for colorectal 
tumorigenesis. Cell 61: 759-767. 
8. Land H, Parada LF, Weinberg R A (1983): Cellular oncogenes and 
multiple carcinogenesis. Science 222: 771-778. 
9. Nowell PC (1986): Mechanisms of tumor progression. Cancer Res 
46: 2203-2207. 
10.Knudson A G (1976): Genetics and the etiology of childhood 
cancer. Pediatr Res 10: 513-517. 
1 I.Kumar V, Cotran RS，Robbins SL (1997): Basic pathology, ed, 
W B Sauders company, Philadelphia, pp 145-174. 
12.Adamson ED (1987): Oncogenes in development. Development 99: 
449-471. 
13. Weinberg R A (1989): Oncogenes, antioncogenes, and the 
molecular bases of multistep carcinogenesis. Cancer Res 49: 3713-
3721. 
- Zheng PP 120 
14.Macleod K (2000): Tumor suppressor genes. Current Opin Genet 
Develop 10: 81-93. 
15.Ponder B (1988): Gene losses in human tumors. Nature 335: 400-
403. 
16.Ali IV, Lidereau R, Theillet C, Callahan R (1988): Reduction to 
homozygosity of genes on chromosome 11 in human breast 
neoplasia. Science 238: 185-188. 
17.Cavenee W K , Dryja TP, Phillips RA, Benedict WF, Godbout R, 
Gallic BL，Murphree AL, Strong LC，White R (1983): Expression 
of recessive alleles by chromosomal mechanisms in retinoblastoma. 
Nature 305: 779-784. 
18.Naylor SL, Johnson BE, Minna JD, Dakaguchi A Y (1987): Loss of 
heterozygosity of chromosome 3p markers in small-cell lung 
cancer. Nature 329: 451-454, 1987. 
19.Volgelstein B，Fearon ER，Hamilton SR, K e m DE, Preisinger AC, 
Leppert M, Nakamura Y, White R, Smits A M , Bos JL (1988): 
Genetic alterations during colorectal-tumor development. N Engl J 
Med 319: 525-532. 
20.Feam ER, Feinber AP, Hamilton SR, Vogelstein B (1985): Loss of 
gene on chromosome 1 Ip in bladder cancer. Nature 318: 377-380. 
21.Green A R (1988): Recessive mechanisms of malignancy. Br J 
Cancer 58: 115-121. 
- Zheng PP 121 
22.Murphree AL, Benedict W F (1984): Retinoblastoma: clue to 
human oncogenesis. Science 223: 1028-1033. 
23.Knudson A G (1985): Hereditary cancer, oncogenes, and 
antioncogenes. Cancer Res 45: 1437-1443. 
24.Hansen M and Cacenee W (1987): Genetics of cancer 
predisposition. Cancer Res 47: 5518-5527. 
25.Cheng KC, Loeb LA (1993): Genomic instability and tumor 
progression: mechanistic considerations, Advances in Cancer 
Research. Academic Press, pp 121-156. 
26.Rodensal N (1994): Molecular medicine. N Engl J Med 331: 315-
317. 
27.Erlich H A (ed) (1989): PCR Technology, Stockton Press, NY, ppl-
244. 
28.Erlich HA, Gelfand D, Saninsky JJ (1991): Recent advances in the 
polymerase chain reaction. Science 252: 1643-1651. 
29.Heiskanen MA, Bittner ML, Chen Y, Khan J, Adler KE, Trent 
JM ,Meltzer PS (2000): Detection of gene amplification by 
genomic hybridization to cDNA microarrays. Cancer Res 60: 799-
802. 
30.ROSS D W (1996): Introduction molecular medicine, ed, 
Springer-verlag New York, Inc., NY, p38-43. 
- Zheng PP 122 
31.Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, 
Gray JW, Pinkel (1994): Optimizing comparative genomic 
hybridization for analysis of D N A sequence copy number changes 
in solid tumors. Genes Chromosomes Cancer 10: 231-243. 
32.Piper H, Rutovitz D, Sudar，Kallioniemi A, Kallioniem OP, 
Waldman FM, Gray JW, Pinkel D (1995): Computer image 
analysis of comparative genomic hybridization. Cytometry 19: 10-
26. 
33.Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner 
A, Dohner H, Cremer T, Lichter P (1997): Matrix-based 
comparative genomic hybridization: biochips to screen for genomic 
imbalances. Gene Chromosomes Cancer 20: 399-407. 
34.Pinkel D, Segraves R, Sudars D, Clark S，Poole I，Kowbel D, 
Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Liung BM, Gray 
JW, Albertson D G (1998): High resolution analysis of D N A copy 
number variation using comparative genomic hybridization to 
microarrays. Nat Genet 2: 207-211. 
35.Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov 
A, Williams CF, Jeffrey SS, Botstein D, Brown PO (1999): 
Genome-wide analysis of D N A copy number changes using cDNA 
micrarrays. Nat Genet 23: 41-46. 
- Zheng PP 123 
36.Hilgers W, Tang DJ, Suger AY, Shekker MC, Hruban R H (1999): 
High-resolution deletion mapping of chromosome Ip in 
pancreatic cancer identifies major consensus region at lp35. 
Genes Chromosomes Cancer 24: 351-355. 
37.Bast Jr RC, Kufe D W , Pollock RE, Weichselbaum RR, Holland JF, 
Frei E (2000): Cancer medicine, B. C. Decker Inc, London, pp 8. 
38.Srivastava S, Ferrell RE (1999): Molecular Pathology of Early 
Cancer. lOS press, NY, pp435-445. 
39.Sato J, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, 
Sakamoto G and Nakamura Y (1990): Allelotype of breast cancer: 
cumulative allele losses promote tumor progression in primary 
breast cancer. Cancer Res 50: 7184-7189. 
40.Fults D, Pedone CA, Thomas FA, White R (1990): Allelotype of 
human malignant astrocytoma. Cancer Res 50: 5784-5789. 
41.Tsuchiya E, Nakamura Y, Weng SY, Nagagawa K, Tsuchiya S, 
Sugano H and Kitagawa T (1992): Allelotype of non-small cell 
lung carcinoma-comparison between loss of heterozygosity in 
squamous cell carcinoma and adenocarcinoma. Cancer Res 52: 
2478-2481. 
42.Cliby W, Ritland S, Hartmann L, Dodson M, Hailing KC, Keeney 
G, Podratz KC, Jenkins RB (1993): Human epithelial ovarian 
cancer allelotype. Cancer Res 53: 2393-2398. 
- Zheng PP 124 
43.Knowles M A , Elder PA, Williamson JP, Cairns JP，Shaw ME, Law 
M G (1994): Allelotype of human bladder cancer. Cancer Res 54: 
531-538. 
44.Fumari F, Huang H, Cavenee W (1995): Genetics and malignant 
progression of human brain tumors. Cancer Surv 25: 233-275. 
45.Cavenee W (1992): Accumulation of genetic defects during 
astrocytoma progression. Cancer 70: 1788-1793. 
46.Zhang L, Zhou W, Velculescu V, K e m S, Hruban R, Hamilton S, 
Vogelstein B, Klinzler K (1997): Gene expression profiles in 
normal and cancer cells. Science 276: 1268-1272. 
47.Caincross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein D M , 
Hammond RR, Siver JS, Stark PC, Macdonald DR, Ino Y, Ramsay 
DA, Louis D N (1998): Specific genetic predictors of 
chemotheraputic response and survival in patients with anaplastic 
oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479. 
48.von Deimling A, von A m m o n K，Schoenfeld D, Wieestler OD, 
Seizinger B R and Louis D N (1993): Subset of glioblastoma 
multiform defined by molecular genetic analysis. Brain Pathol 3: 
19-26. 
49.Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, 
Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von 
- Zheng PP 125 
Deimling A (1997): Molecular genetic evidence for subtypes of 
oligoastrocytomas. J Neuropathol Exp Neurol 56: 1098-1104. 
SO.Ebert C, von Haken M，Meyer-Puttlitz B, Wiestler OD, 
Reifenberger G, Pietsch T, von Deimling A (1999): Molecular 
cytogenetic analysis of ependymal tumors. NF2 mutations and 
chromosome 22q loss occur preferentially in intramedullary spinal 
ependymomas. A m J Pathol 155: 627-632. 
51 .Ferraccio F and Accardo M (1994): Cytometry of ependymomas 
using Feulgen-positive DNA. Pathokogica 86: 360-365. 
52.Harada K, Nishizaki T, Ozaki Satoshi, Kubota H, Ito H and Sasaki 
K (1998): Intratumoral cytogenetic heterogeneity detected by 
comparative genomic hybridization and laser scanning cytometry 
in human gliomas. Cancer Res 58: 4694-4700. 
53.Boehm T, Folkman J, Brower T and O'Reilly M S (1997): 
Antiangiogenetic therapy of experimental cancer does not induce 
acquired drug resistance. Nature 390: 404-407. 
54.Greller LD, Tobin FL and Poste G (1996): Tumor heterogeneity 
and progression: conceptual foundations for modeling. Invasion 
Metastasis 16: 177-208. 
55.Thibodeau SN, Bren G. Schaid D (1993): Microsatellite instability 
in cancer of the proximal colon. Science 260: 816-819. 
- Zheng PP 126 
56.Hamilton RL and Pollack IF (1997): The molecular biology of 
ependymomas. Brain Pathol 7: 807-822. 
57.Mork SJ, Loken A C (1977): Ependymoma: a follow-up study of 
101 cases. Cancer 40: 907-915. 
5 8.Epstein FJ，Farmen JP, Freed D (1993): Adult intramedullary 
spinal cord ependymomas: the result of surgery in 38 patients. J 
Neurosurg 79: 204-209. 
59.McCormick PC, Tores R, Post KD, Stein B M (1990): 
Intramedullary ependymoma of the spinal cord. J Neurosurg 72: 
523-532. 
60.Whitaker SJ, Bessell EM, Ashley SE, Bloom HJ, Beld BA, Brada 
M (1991): Postoperative radiotherapy in the management of spinal 
cord ependymoma. J Neurosurg 74: 720-728. 
61.Rawlings CED, Giangaspero F, Burger PC, Bullard DE (1988): 
Ependymomas: a clinicopathologic study. Surg Neurol 29: 271-281. 
62.Read G (1984): The treatment of ependymoma of the brain or 
spinal canal by radiotherapy: a report of 79 cases. Clin Radiol 35: 
163-166. 
63.Schiffer D, Chio A, Cravioto H, Giodana MT, Migheli A, Soffietti 
R, Vigliani M C (1991): Ependymoma: internal correlations among 
pathological signs: the anaplastic variant. Neurosurg 29: 206-210. 
Zhene PP 127 � 
64.Akyuz C，Emir S, Akalan N, Soylemezoglu F, Kutluk T, 
Buyukpamukcu M (2000): Intracranial ependymomas in 
childhood—a retrospective review of sixty-two children 
ependymoma. Acta Oncol 39: 97-100. 
65.Russel, D D and Rubinstein LJ (1977): Pathology of tumors of the 
central nervous system, Baltimore M D : Williams & Wilkins, pp 
204-206. 
66.Bouffet E, Perilongo G, Ganete A, Massimino M (1998): 
Intracranial ependymomas in children: A critical review of 
prognostic factors and a plea for cooperation. Med Pediatr Oncol 
30: 319-331-351. 
67.Healey EA, Barnes PD, Kupsky WJ, Scott RM, Sallan SE, Black 
PM, Tarbell NJ (1991): The prognostic significance of 
postoperative residual tumor in ependymoma. Neursurg 28: 666-
672. 
68.Heideman R, Parker RJ, Albright LA, Freeman CR, Rorke LB 
(1997): Tumor of the CNS. In: Principle and Practice of Pediatric 
Oncology, 3th Ed. PA Pizzo, D G Poplack, eds. JB Lippincott 
company, Philadelphia, pp 633-698. 
69.Kleihues P，Cavenee W K (ed) (2000): Pathology & genetics of 
tumor of the nervous system, lARC Press, Lyon, pp 72-86. 
- Zheng PP 128 
70.Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, Finlay JL 
(1996): Adjuvant chemotherapy of childhood posterior fossa 
ependymoma: cranio-spinal irradiation with or without adjuvant 
CCNU, vincristine, and prednisone: a Children Cancer Group 
Study. Med Pediatr Oncol 27: 8-14. 
71.Papadopoulos DP, Giri S, Evans R G (1990): Prognostic factors and 
mangement of intracranial ependymomas. Anticancer Res 10: 689-
692. 
72.Barone BM, Elvidge A R (1970): Ependymomas. A clinical survey. 
JNeursurg33: 428-438. 
73.Ferrante L, Mastronardi L, Schettini G, Lunardi P, Fortuna A 
(1994): Fourth ventricle ependymomas. A study of 20 cases with 
survival analysis. Acta Neurochir 131: 67-74. 
74.Duncan JA III and Hoffman (1995): Intracranial ependymomas: In: 
Brain Tumors. Kay AH, Laws ER Jr, eds. Churchill Livngstone Inc. 
New York, pp 493-504. 
75.Lyons MK,Kelly PJ (1991): Posterior fossa ependymomas: report 
of 30 cases and review of the literature. Nerurosurg 28: 659-664. 
76.Rousseau P, Habrand JL, Sarrazin D, Kalifa C, Terrier-Lacombe 
MJ, Rekacewicz C, Rey A (1994): Treatment of intracranial 
ependymomas of children: review of 15 year experience. Int J 
Radiat Oncol Biol Phys 28: 381-386. 
- Zheng PP 129 
77.Bloom HJ, Glees J，Bell J, Ashley SE, Gorman C (1990): The 
treatment and long-term prognosis of children with intracranial 
tumors: a study of 610 cases, 1950-1981. Int J Radiat Oncol Biol 
Phys 18: 723-745. 
78.Emestus RI, Schroder R, Stutzer H, Klug N (1996): Prognostic 
relevance of localization and grading in intracranial ependymomas 
of childhood. Childs Nerv Syst 12: 522-526. 
79.Figarella-Branger D, Gambarelli D, Dollo C, Devictor B, Perez-
Castillo A M , Genitori L, Lena G m Choux M, Pellissier JF (1991): 
Infratentorial ependymomas of childhood. Correlation between 
histological features, immunohistological phenotype, silver 
nucleolar organizer region staining values and post-operative 
survival in 16 cases. Acta Neuropathol 82: 208-216. 
SO.Kovalic JJ, Flaris N, Grigsby PW, Pirkowski M, Simpson JR, Roth 
K A (1993): Intracranial ependymomas long-term outcome, patterns 
of failure. J Neuro-Onc 15: 125-131. 
Sl.Ikezaki K, Matsushima T, Inoue T, YokoyamaN, Kaneko Y, Fukui 
M (1993): Correlation of microanatomical localization with post-
operative survival in posterior fossa ependymomas. Neurosurg 32: 
38-44. 
82.Duffher PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, 
Cohen ME, Sanford RA, Mulhem RK, James HE, Freeman CR 
- Zheng PP 130 
(1993): Postoperative chemotherapy and delayed radiation in 
children less than three years of age with malignant brain tumors. 
N E n g JMed328: 1725-1731. 
83.Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P，Albright 
AL, Wisoff JH, Milstein JM, Allen JC，Finlay JL (1994): Survival 
of infants with primitive neuroectodermal tumor or malignant 
ependymomas of the CNS treated with eight drugs in 1 day: a 
report from the Childrens Cancer Group. J Clin One 12: 1607-1615. 
84.Folkes EW, Earle K M (1969): Ependymomas: clinical and 
pathological aspects. J Neurosurg. 30: 588-594. 
85.Bloom HJG (1982): Intracranial tumors: response and resistance to 
theraputic endeavors, 1977-1980. Int J Radiat Onclo Biol Phys 8: 
1083-1113. 
86.Cohen ME, Duffiner PK (eds) (1984): Brian tumors in children. 
Principles and diagnosis and treatment, New York: Raven Press, pp 
136-155. 
87.Farewell JR, Dohrmann ZFJ, Farmery JT (1977): Central nervous 
system tumors in children. Cancer 40: 3113-3123. 
88.Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright 
cvAL, Janosky J，Deutsch M (1995): Intracranial ependymomas of 
childhood: long-term outcome and prognostic factors. Neursurg 37: 
655-666. 
- Zheng PP 131 
89.Goldwein JW, Leahy JM, Packer RJ，Sutton LN, Curran WJ, Rorke 
LB, Schut L，Littman PS, D'Angio GJ (1990): Intracranial 
ependymomas in children. Int J Radiat Oncol Biol Phys 19: 1497-
1502. 
90.Shuman RM, Alvord EC, Jr, Leech R W (1975): The biology of 
childhood ependymomas. Arch Neurol 32: 731-739. 
91.Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, Finlay JL 
(1996): Adjuvant chemotherapy of childhood posterior fossa 
ependymoma: cranio-spinal irradiation with or without adjuvant 
CCNU, vincristine, and prednisone: a Children Cancer Group 
study. Med Pediatr Oncol 27: 8-14. 
92.Rousseau P, Habrand JL, Sarrazin D, Kalifa C, Terrier-Lacombe 
MJ, Rekacewicz C, Rey A (1994): Treatment of intracranial 
ependymomas of children: review of a 15 year experience. Int 
Radiat Oncol Biol Phys 28: 381-386. 
93.Needle M N , Goldwein JW, Grass J, Cnaan A, Bergman I, Molloy 
P, Sutton L, Zhao H，Garvin JH Jr, Phillips (1997): Adjuvant 
chemotherapy for the treatment of intracranial ependymoma of 
childhood. Cancer 80: 341-347. 
94.Kleinman GM, Young RH, Scully RE (1984): Ependymoma of the 
ovary: A report of three cases. Hum Pathol 15: 632-637. 
- Zheng PP 132 
95.Yang-Feng TL, Katz SN，Cacangiu ML, Schwarts PE (1998): 
Cytogenetic analysis of ependymoma and teratoma of the ovary. 
Cancer Genet Ctyogenet 35: 89-93. 
96.Salazar O M , Rubin P, Bassano D，Marcial V A (1975): Improved 
survival of patients with intracranial ependymomas by irradiation: 
dose selection and field extention. Cancer 35: 1563-1573. 
97.Goldwein JW, Glauser TA, Packer RJ, Finlay JL, Sutton LN， 
CurranWJ, Laehy JM, Rorke LB, Schut, D'Angio GJ (1990): 
Recurrent intracranial ependymomas in children. Survival, pattern 
of failure, and prognostic factors. Cancer 66: 557-563. 
98.Salazar D M (1983): A better understanding of CNS seeding and a 
brighter outlook for postoperatively irradiated patients with 
ependymomas. Int J Radiat Oncol Biol Phys 9: 1231-1234. 
99.Foreman NK, Love S, Thome R (1996): Intracranial ependymomas: 
Analysis of prognostic factors in population-based series. Pediatr 
Neurosurg 24: 119-125. 
100. Merchant TE, Haida T，Wang MH, Finlay JL, Leibel (1997): 
Anaplastic ependymoma: Treatment of pediatric patients with or 
without craniaospinal radiotherapy. J Neurosurg 86: 943-949. 
101. Sutton LN, Goldwein J, Perilongo G, Lang B, Schut L, 
Rorke L, Packer (1990/1991): Prognostic factors in childhood 
ependymomas. Pediatr Neurosurg 16: 57-65. 
- Zheng PP 133 
102. Gerszten PC, Pollack IF, Martinez AJ, Lo KH, Janosky J, 
Albright A L (1996): Intracranial ependymomas of childhood-lack 
of correlation of histopathology and clinical outcome. Pathol Res 
Prac 192:515-522. 
103. Ross GW，Rubinstein LJ (1989): Lack of histopathological 
correlation of malignant ependymomas with postoperative survival. 
J Neurosurg 70: 31-36. 
104. Undjian S, Marinov M (1990): Intracranial ependymomas in 
children. Childs Nerv Syst 6: 131-134. 
105. Vanuytsel LJ, Besselle EM, Ashley SE, Bloom HJ, Brada M 
(1992): Incranial ependymomas: long-term results of policy of 
surgery and radiotherapy. Int Radiat Oncol Biol Phys 23: 313-319. 
106. Shaw EG, Evan RG, Scheithauer B W m Listrup D M , Earle 
JD (1987): Postoperative radiotherapy of intractmial ependymoma 
in pediatrc and adult patients. Int J Radiat Oncol Biol Phys 13: 
1457-1462. 
107. Pollack IF (1994): Brain tumors in children. N Engl J Med 
331: 1500-1507. 
108. Read G (1984): The treatment of ependymoma of the brain 
or spinal canal by radiotherapy: a report of 79 cases. Clin Radiol 35: 
163-166. 
- Zheng PP 134 
109. Rorke L, Gilles F, Davis R, Becker L (1985): Revision of the 
World Health Organization classification of brain tumors. Cancer 
56: 1869-1886. 
110. Rushing RJ, Yashima K, Brown DF, White CL，Shay JM, 
Risser RC, Gazdar A E (1997): Expression of telomerase R N A 
component correlates with the MIB-1 proliferation index in 
ependymomas. J Neuropathol Exp Neurol 56: 1142-1146. 
111. Asai A, Hosjino T，Edwards MS, Davis RL (1992): 
Predicting the recurrence of ependymomas from the 
bromodeoxyuridine labeling index. Childs Nerv Syst 8: 273-278. 
112. Nagashima T, Hoshino T, Cho KG, Edwards MS, Hudgins 
RJ, Davis RL (1988): The proliferative potential of human 
ependymomas measures by in situ bromodeoxyuridine labeling. 
Cancer 61: 2433-2438. 
113. Prayson R A (1999): Clinocopathologic study of 61 patients 
with ependymomas including MIB-1 immunohistochemistry. Ann 
Diagn Pathol 3: 8-11. 
114. Rushing EJ, Brown DF, Hladik CL, Risser RC, Mickey BE, 
White CL 3rd (1998): Correlation of bcl-2, p53 and MIB-1 
expression with ependymoma grade and subtype. J Neuropathol 
Exp Neurol 11: 464-470. 
- Zheng PP 135 
115. Battifora H (1997): The telomerase story: No end in sight? 
A m J Clin Pathol 107: 555-560. 
116. Morin G B (1995): Is telomerase a universal cancer target? J 
Natl Cancer Inst 87: 859-861. 
117. Lundblad V, Wright W E (1996): Telomeres and telomerase: 
A simple picture becomes complex. Cell 87: 369-375. 
118. Harley CB, Villeponteau B (1996): Telomeres and 
telomerase in aging and cancer. Curr Opin Gen Dev 5: 249-255. 
119. Vagner-Capodano, Zattara-Cannoni H, Gambarelli D, 
Figarella-Branger D, Lena G, Dufour H, Grisoli F, Choux M 
(1999): Cytogenetic study of 33 ependymomas. Cancer Genet 
Cytogenet 115: 96-99. 
120. Mazewski C, Soukup S，Ballard E, Gotwals B, Lampkin B 
(1999): Karyotype studies in 18 ependymomas with literature 
review of 107 cases. Cancer Genet Cytogenet 113: 1-8. 
121. Bhattacharjee MB, Armstrong DD, Vogel H, Cooley LD 
(1996): Cytogenetic analysis of 120 primary pediatric brain tumors 
and literature review. Cancer Genet Cytogenet 97: 39-53. 
122. Straton MR, Darling J, Lantos PL, Cooper CS, Reeves B R 
(1989): Cytogenetic abnormalities in human ependymomas. Int J 
Cancer 44: 579-581. 
- Zheng PP 136 
123. Ragatto SR, Casartelli C，Rainho CA, Barbieri-Neto J (1993): 
Chromosomes in the genesis and progression of ependymomas. 
Cancer Genet Cytogenet 69: 146-152. 
124. Grinffin CA, Long PP, Carson BS, Brem H (1992): 
Chromosome abnormalities in low-grade central nervous system 
tumors. Cancer Genet Cytogenet 60: 67-73. 
125. Jenkins RB, Kimmel D W , Moertel CA, Schultz CG, 
Scheithauer B W , Kelly PJ, Dewald G W (1989): A cytogenetic 
study of 53 human gliomas. Cancer Genet Cytogenet 39: 253-279. 
126. Neumann E, Kalousek DK, Norman M G , Steinbok P, 
Cochrane DD, Goddard K (1993): Cytogenetic analysis of 109 
pediatric central nervous system tumors. Cancer Genet Cytogenet 
71 : 40-49. 
127. Nijssen PC, Deprez RH, Tijssen CC, Hagemeijer A, 
Amoldus EP, Teepen JL, Holl R, Niermeyer M F (1994): Familial 
anaplastic ependymomas: evidence of loss of chromosome 22 in 
tumor cells. J Neurol Neurolsurg Psychiat 57: 1245-1248. 
128. Park JP, Chaffee S, Noll W W , Rhodes C H (1996): 
Constitutional de novo t(l,22) (p22;qll.2) and ependymoma. 
Cancer Genet Cytpogenet 86: 150-152. 
129. Ransom DT, Ritland SR, Kimmel D W , Moertel CA, Dahl 
RJ, Scheithauer BW, Kelly PJ, Jenkions RB (1992): Cytogenetic 
- Zheng PP 137 
and loss of heterozygosity studies in ependymomas, pilocytic 
astrocytomas, and oligodendrogliomas. Gene Chromosomes 
Cancer 5: 348-356. 
130. Rey JA, Bello MJ, de Campos JM, Kusak ME, Moreno S 
(1987): Chromosomal composition of a series of 22 human low-
grade gliomas. Cancer Genet Cytogenet 29: 223-237. 
131. Sawyer JR, Sammartino G, Husain M, Boop FA, Chadduck 
W M (1994): Chromosome aberrations in four ependymomas. 
Cancer Genet Cytogent 74: 132-138. 
132. Vagner-Capodano A M , Center JC, Gambarelli D, Pellissier 
JF，Gouzien M, Lena G，Genitori L, Choux M, Raybaud C (1992): 
Cytogenetic studies in 45 pediatric brain tumors. Pediatr Hematol 
Oncol 9: 223-235. 
133. Weremowicz S, Kupsky WJ, Morton CC, Fletcher JA (1992): 
Cytogenetic evidence for a chromosome 22 tumor suppressor gene 
in ependymoma. Cancer Genet Cytogenet 61: 193-196. 
134. Slave I, MacCollin M M , Dunn M，Jones S, Sutton L, 
Gusella JF, Biegel JA (1995): Exon scanning for mutations of NF2 
gene in pediatric ependymomas, rhabdoid tumors, and 
meningiomas. Int J Cancer 64: 243-247. 
135. Rubio MP, Correa KM, Ramesh V, MacCollin M M , Jacoby 
LB, von Deimling A, Gusell JF, Louis D N (1994): Analysis of the 
- Zheng PP 138 
neurofibromatosis 2 gene in human ependymomas and 
astrocytomas. Cancer Res 54: 45-47. 
136. James CD, JU He, Carlbom E, Mikkelsen T, Rodderheim P-
A, Cavenee W K , Collin VP (1990): Loss of genetic information in 
central nervous system tumors common to children and young 
adults. Gene Chromosomes Cancer 2: 94-102. 
137. Rey J A, Bello MJ, de Campos JM, Vaquero J, Kusak ME, 
Sarasa JL, Pestana A (1993): Abnormalities of chromosome 22 in 
human brain tumors determined by combined cytogenetic and 
molecular genetic approaches. Cancer Genet Cytogenet 66:1-10. 
138. Trofatter J A, MacCollin M M , Rutter JL, Murrell JR, Duyao 
MP, Parry D M , Eldridge R, Kley N, Menon AG, Pulaski K, Haase 
VH, Ambrose CM, Bove C, Haines JL, Martaza RL, MacDonald 
ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF (1993): The 
neurofibromatosis tumor suppressor gene encodes a novel moesin-
ezrin-radxin-like-protein. Cell 72: 791-800. 
139. Rouleau GA, Merel O，Lutchman M, Sanson M, Zucman J, 
Marlineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougaste 
B, Pulst SM, Lenoir G, Bijisma EM, Fashold R, Dumanski J, de 
Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G 
(1993): Alteration in a new gene encoding a putative membrane-
- Zheng PP 139 
organizing protein causes neurobromatosis type 2. Nature 363: 
515-521. 
140. Evans DGR, Huson SM, Donnai D, Neary W , Blair V, Teare 
D，Newton V, Strachen T，Ransden R，Harris R (1992): A genetic 
study of type 2 neurofibromatosis in the United Kindom: I-
Prevalence, mutation rate, fitness, and confirmation of maternal 
transmission effect on severity. J Med Genet 29:841-846. 
141. Martuza RL, Eldridge R (1988): Neurofibroomatosis 2 
(bilateral acoustic neurofibromatosis). New Engl J Med 318: 684-
688. 
142. Martuza RL, Ojemann R G (1982): Bilateral acoustic 
neuromas: Clinical aspects, pathogenesis and treatment. Neurosurg 
10: 1-12. 
143. Russell DS, Rubinstein LJ (1989): Pathology of tumors of 
the nervous system, edition. Williams and Wilkins, Baltimore. 
144. Hoang-Xuan K，Mere P, Vega F, Hugot JP, Comu P, 
Delattre JY, Poisson M, Thomas G, Delattre O (1995): Analysis of 
the NF2 tumor-suppressior gene and of chromosome 22 deletions 
in gliomas. Int J Cancer 60: 478-481. 
145. Birch BD, Johnson JP, Parsa A，Desai RD, Yoon JT, Lylette 
CA, Li YM, Bruce JN (1996): Frequent type 2 neurofibromatosis 
- Zheng PP 140 
gene transcript mutations in sporadic intramedullary spinal cord 
ependymomas. Neurosurg 39: 135-140. 
146. von Haken MS, White EC, Daneshvarshyesther L, Sih S， 
Choi E，Kalra R, Cogen PH (1996): Molecular genetic analysis of 
chromosome arm 17p and chromosome are 22q D N A sequences in 
sporadic ependymomas. Gene Chromosome Cancer 17: 37-44. 
147. Bijlsma EK, Voesten A M , Bijleveld EH, Troost D, 
Westerveld A, Merel P, Thomas G, Hulsebos TJ (1995): Molecular 
analysis of genetic changes in ependymomas. Gene Chromosome 
Cancer 13: 272-277. 
148. Huynh DP, Mautner V，Baser ME, Stavrou D, Pulst S M 
(1997): Immunohistochemical detection of schwannomin and 
neurobromin in vestibular schwannomas, ependymomas, and 
meningiomas. J Neuropathol Exp Neurol 54: 382-390. 
149. Verstege I, Sevenet N, Lange J, Rousseau-Merk MF, 
Ambros P, Handgretinger R, Aurias A, Delattre O (1998): 
Truncating mutations of hSNF5/INIl in aggressive pediatric cancer. 
Nature 394: 203-206. 
150. Muchardt C, Sardet C, Bourachot B, Onufryk C，Yaniv M 
(1995): A human protein with homology to Saccharomyces 
cerevisiae SNF5 interacts with the potential helicase hbrm. Nucleic 
Acid Res 23: 1127-1132. 
Zheng PP 141 
151. Kalpana GV, Marmon S, Wang W, Crabtree GR，Groff SP 
(1994): Binding and stimulation of HIV-1 integrase by a human 
homolog of yeast transcription factor SNF5. Science 266: 2002-
2006. 
152. Peterson CL (1996): Multiple switches to turn on chromatin? 
Curr Opin Genet Dev 6: 171-175. 
153. Wang W , Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree G R 
(1996): Diversity and specialization of mammalian SWI/SNF 
complexes. Gene Dev 10: 2111-2130. 
154. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, 
Ambros P, Handgretinger R, Aurias A, Delatte O (1998): 
Truncating mutations of hSNF5/INIl in aggressive pediatric cancer. 
Nature 394: 203-306. 
155. Gerken SC, Abertsen H, Eisner T, Ballard L, Holik P, 
Lawrence E，Moore M, Zhao X，White R (1995): A strategy for 
constructing high-resolution genetic maps of the human genome: A 
genetic map of chromosome 17p, ordered with meiotic breakpoint-
mapping panel. A m J H u m Genet 56: 484-499. 
156. Wernicke C，Thiel G, Lozanova T, Vogel S, Kintzel D, 
Janishch W, Lehmann K, Witkowski R (1995): Involvement of 
chromosome 22 in ependymomas. Cancer Genet Cytoget 79: 173-
176. 
Zheng PP 142 
157. Metzger AK, Sheffield VC, Duyk G, Daneshvar L, Edwards 
MSB, Cogen PH (1991): Identification of a germ-line mutation in 
p53 gene in a patient with an intracranial ependymoma. Proc Natl 
Acad Sci U S A 88:7825-7829. 
158. Tong CYK, Ng HK, Pang JCS, Hui ABY，Ko H C W , Lee 
JCK (1999): Molecular genetic analysis of non-astrocytic gliomas. 
Histopathol 34:331-341. 
159. Orellana C, Hermandez-Marti M, Martinez F, Castel V, 
Millan JM, Alvarez-Garijo JA, Prieto F, Badia L (1997): Pediatric 
brain tumors: loss of heterozygosity at 17p and TP53 gene 
mutations. Cancer Gene Cytogenet 102: 93-99. 
160. Ohgaki H，Eibl RH, Wiestler OD，Yasargil M G , Newcomb 
EW, Kleihues P (1991): p53 mutatios in nonastrocytic human 
brain tumors. Cancer Res 51: 6202-6205. 
161. Fink KL, Rushing EJ, Schold SC Jr, Nisen PD (1996): 
Infrequency of p53 gene mutations in ependymomas. J Neurooncol 
27: 111-115. 
162. Kramer DL, Parmiter AH, Rorke LB, Sutton LN, Biegel JA 
(1998): Molecular cytogenetic studies of pediatric ependymomas. 
Lab Invest 37: 25-33. 
163. Amoldus EP, Wolters LB, Woormolen JK, van Duinen SG, 
Raap AK, van der Ploeg M, Peter AC (1992): Interphase 
Zheng PP 143 
cytogenetics: a new tool for the study of genetic changes in brain 
tumors. J Neurosurg 76 : 997-1003. 
164. Alimov A, Kost-Alimova M，Liu J, L CD, Bergerheim UIF, 
Imreh S, Klein G，Zabarovsky ER (2000): Combined LOH/CGH 
analysis proves the existence of interstitial 3p deletions in renal cell 
carcinoma. Oncogene 19: 1392-1399. 
165. Bentz M, Plesch A, Stilgenbauer S, Dohner H, Lichter P 
(1998): Minimal sizes of deletions detected by comparative 
genomic hybridization. Gene Chromosome Cancer 21: 172-175 
166. Tischfield JA (1997): Loss of heterozygosity or: how I 
learned to stop worrying and love mitotic recombination. A m J 
H u m Genet 61: 995-999. 
167. James CD, Carbom E, Nordenskjold M, Collin VP, Cavenee 
W K (1989): Mitotic recombination of chromosome 17 in 
astrocytomas. Proc Natl Acad Sci USA 86: 2858-2862 
168. Chemova 〇，Cowell JK (1998): Molecular definition of 
chromosome translocation involving 10q24 and 19ql3 in human 
glioma cells. Cancer Genet cytogenet 105: 60-68. 
169. Maniatis T, Fritsoh EF，Sambrook J (1989): Molecular 
Cloning: a Laboratory Manual, Cold Spring Harbor Press, Cold 
Spring, 2nd ed, p280-281. 
Zheng PP 144 
170. Knowles M A (1996): Methods in molecular genetics., 
Academic Press, Inc., NY, pp 116 
171. Hui ABY, Pang JCS, Ko CW, Ng H K (1999): Detection of 
chromosomal imbalances in growth homone-secreting pituitary 
tumors by comparative genomic hybridization. Human Pathol 30: 
1019-1023 
172. Jian L, Zabarovska VI, Braga E, Alimov A, Klein G, 
Zabarovsky ER (1999): Loss of heterozygosity in tumor cells 
requires re-evaluation: The data are biased by the size-dependent 
differential sensitivity of allele detection. FEBS Letter 462: 121-
128. 
173. Ransom DT, Ritland SR, Moetrel CA, Pahl RJ, O'Fallon JR, 
Scheithauer BW, Kimmel D W , Kelly PJ, Olopade OL, Diaz MO, 
Jenkins RB (1992): Correlation of cytogenetic and loss of 
heterozygosity studies in human astrocytomas and mixed 
oligoastrocytomas. Gene Chromosme Cancer 5: 357-374. 
174. Rey JA, bello MJ, de Campos JM, Kusak ME, Moreno S 
(1987): Chromosomal composition of a series of 22 human low-
grade gliomas. Cancer Genet Cytogenet 29: 223-237. 
175. Ng HK, Lau KM, Tse JYM, Lo KW, Wong JHC, Poon WS, 
Huang DP (1995): Combined molecular genetic studies of 
Zheng PP 145 
chromosome 22q and the neurofibromatosis type 2 gene in central 
nervous tumors. Neurosurg 37: 764-773. 
176. Okamoto M, Sasak M, Sgio K, Sato C, Iwama T, Ikeuchi T, 
Tonomara A, Sasazaki T, Miyaki M (1988): Loss of constitutional 
heterozygosity in colon carcinoma from patients with familial 
polyposis coli. Nature 331: 273-277. 
177. Flejter WL, Li PP, Antmen KH, Testa JR (1989): Recurring 
loss of chromosomes 1, 3 and 22 in malignant methothelioma. 
Possible sites of tumor suppressor genes. Genes Chromosomes 
Cancer 1: 148-154. 
178. Fletcher KA, Lipinski KM, Corson JM, Morton CC (1989): 
cytogenetic of peripheral nerve sheath tumors. Cancer Genet 
Cytogenet41: 224. 
179. Saito S, Sirahama S, Matsushima M, Suzuki M, Sagae S, 
Kudo R,Saito J, Noda K, Nakamura Y (1996): Definition of a 
commonly deleted region in ovarian cancers to 300-kb segment of 
chromosome 6q27. Cancer Res 56: 5586-5589. 
180. Suzuki M, Saito S, Saga Y, Ohwada M, Sato I (2000): 
Mutation of K-ras protooncogene and loss of heterozygosity on 
6q27 in serious mucinous ovarian carcinomas. Cancer Genet 
Cytogenet 118: 132-135. 
Zheng PP 146 
181. Kuriyama M, Harada N，Kuroda S, yamamoto T, NakafUku 
M，Iwamatsu A, Yamamoto D，Prassad R, Croce C, Canaani E， 
Kaibuchi K (1996): Identification of AF-6 and canoe as putative 
targets for Ras. J Biol Chem 271: 607-610. 
182. Yamamoto T，Harad N, Kano K, Taya S, Canaai E, 
Matsuura Y, Mizoguchi A, Ide C, Kaibuchi K (1997): The Ras 
target AF-6 interacts with ZO-1 and serves as a peripheral 
componenetof tight junctions in epithelial cells. J Cell Biol 139: 
785-795. 
183. Prasad R, Gu Y, Alder H，Nakamura T, Canaani O, Saito H， 
Huebner K，Gale RP, Nowell PC, Kuriyama K, Miyazaki Y, Croce 
CM, Canaani E (1993): Cloning of ALL-1 fusion partner, the AF-6 
gene, involved in acute myeloid leukemias with the t (6; 11) 
chromosome translocation. Cancer Res 53: 5624-5628. 
184. Thomas GA, Raffel C (1991): Loss of heterozygosity on 6q, 
16q and 17p in human central nervous system primitive 
neuroectodermal tumors. Cancer Res 51: 639-64. 
185. Wan M, Sun T, Vyas R，Zheng J, Granada E, Dubeau L 
(1999): Suppression of tumorigenicity in human ovarian cancer 
cell lines is controlled by a 2cM fragment in chromosomal region 
6q24-q25. Oncogene 18: 1545-1551. 
Zheng PP 147 
186. Jackson A, Carrara P, Duke V, Sinclair P, Papaioannou M, 
Harrison CJ, Foroni L (2000): Deletion of 6ql6-q21 in human 
lymphoid malignancies: a mapping and deletion analysis. Cancer 
Res 60 :2775-2779. 
187. Huang SF, Hsu HC, Cheng Y M , Chang TC (2000): Allelic 
loss at chromosome band 6ql4 correlates with favorable prognosis 
in hepatocellular carcinoma. Cancer Genet Cytogenet 116 :23-27. 
188. Qu XY, Hauptschein RS, Rzhetsky A，Scotto L, Chien MC, 
Ye X, Frigeri F, Rao PH, Pasqualucci L, Gamberi B, Deaven LL, 
Zhang P, Chaganti RS, Dalla-Favera R, Russo JJ (1998): Analysis 
of a 69-kb contiguous genomic sequence at a putative tumor 
suppressor gene locus on human chromosome 6q27. D N A Seq 
9 :189-204. 
189. Hatta Y, Yamada Y, Tomonaga M, Miyoshi I, Said JW, 
Koeffler HP (1999): Detailed deletion mapping of the long arm of 
chromosome 6 in adult T-cell leukemia. Blood 93 :613-616. 
190. Hauptschein RS, Gamberi B, Rao PH, Frigeri F, Scotto L, 
Venkatraj VS, Gaidano G, Rutner T, Edwards YH, Chaganti RS, 
Dalla-Favera R (1998): Cloning and mapping of human 
chromosome 6q26-q27 deleted in B-cell non-Hodgkin lymphoma 
and multiple tumor types. Genomics 50 •  170-186. 
Zheng PP 148 
191. Merup M, Moreno TC, Heyman M, Romberg K，Grander D， 
Detlofsson R, Rasool O, Liu Y，Soderhall S, Juliusson G, Gahrton 
G, Einhom S (1998): 6q deletions in acute lymphoblastic leukemia 
and non-Hodgkin's lymphomas. Blood 91 :3397-3400. 
192. Pastore C, Carbone A, Gloghini A, Volpe G, Saglio G, 
Gaidano G (1996): Association of 6q deletions with AIDS-related 
diffuse large cell lymphoma. Leukemia 10 :1051-1053. 
193. Parsa NZ, Gaidano G, Mukherjee AB, Hauptschein RS, 
Lenoir G，Dalla-Favera R, Chaganti RS (1994): Cytogenetic and 
molecular analysis of 6q deletions in Burkitt's lymphoma cell lines. 
Genes Chromosomes Cancer 9:13-18. 
194. Offit K, Parsa NZ, Gaidano G, Filippa DA, Louie D, Pan D, 
Jhanwar SC, Dalla-Favera R, Chaganti RS (1993): 6q deletions 
define distinct clinico-pathologic subsets of non-Hodgkin's 
lymphoma. Blood 82 :2157-2162. 
195. Gaidano G, Hauptschein RS, Parsa NZ, Offit K, Rao PH, 
Lenoir G, Knowles DM, Chaganti RS, Dalla-Favera R (1992): 
Deletions involving two distinct regions of 6q in B-cell non-
Hodgkin lymphoma. Blood 80 :1781-1787. 
196. McLendon RE, Fung KM, Bentley RC, Rasheed BKA, 
Trojanowski JQ, Binger SH, Dinger DD, Friedman HS (1996): 
- Zheng PP 149 
Production and characterization of two ependymoma xenografts. J 
Neuropathol Exp Neurol 55: 540-548. 
197. Griffin CA, Hawkins AL, Packer RJ, Borke LB, Emanuel 
BS (1988): Chromosome abnormalities in pediatric brain tumors. 
Cancer Res 48: 175-180. 
198. Lininger RA, Park WS, Man YG, Pham T, MacGrogan G, 
Zhuang Z, Tavassoli FA (1998): L O H at 16pl3 is a novel 
chromosomal alteration detected in benign and malignant 
microdissected papillary neoplasms of the breast. H u m Pathol 29: 
1113-1118. 
199. Filippova GN, Lindblom A, Meincke LJ, Klenova EM, 
Neiman PE, Collins SJ, Doggett NA, Lobanenkov V V (1998): A 
widely expressed transcription factor with multiple D N A sequence 
specificity, CTCF, is localized to a chromosome segment 16q22.1 
within one of the smallest regions of overlap for common deletions 
in breast and prostate cancers. Genes Chromosomes Cancer 22: 26-
36. 
200. Shearer PD, Valentine MB, Grundy P, DeCou JM, Banavali 
SD, Komuro H，Green D M , Beckwith JB，Look A T (1999): 
Hemizygous deletion of chromosome band 16q24 in Wilms tumor: 
detection by fluorescence in situ hybridization. Cancer Genet 
Cytogenet 115: 100-105. 
Zheng PP 150 
201. McGhee EM, Cohen NR, Wolf JL, Ledesma CT, Cotter PD 
(2000): Monosomy 16 as the sole abnormality in myeloid 
malignancies. Cancer Genet Cytogenet 118: 163-166. 
202. Semb H，Christofori G (1998): The tumor-suppressor 
function of E-cadherin. A m J H u m Genet 63: 1588-1593. 
203. Shlomit R, Ayala AG, Michal D, Ninett A, Frida S, 
Boleslaw G，Gad B，Gideon R, Shlomi C (2000): Gains and losses 
of D N A Sequences in childhood brain tumors analyzed by 
comparative genomic hybridization. Cancer Genet Cytogenet 121: 
67-72. 
204. Rogatto SR, Casartelli C, Rainho CA，Barbieri-Neto J 
(1993): Chromosome is the genesis and progression of 
ependymomas. Cancer Genet cytogenet 69: 146-152. 
205. Peter N, Smith JS, Tachibana I, Lee HK, Pohl U, Portier BP, 
Louis DN, Jenkins RB (1999): The human glia maturation factor-
gamma gene: genomic structure and mutation analysis in gliomas 
with chromosome 19q loss. Neurogenetics 2: 163-166. 
206. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler 
W, Collins VP (1994b): Molecular genetic analysis of 
oligodendroglial tumors shows preferential allelic deletions on 19q 
and Ip. A m J Pathol 145: 1175-1190. 
Zheng PP 151 
207. von Deimling A, Nagel J, Bender B, Zlenartz D, Schramm J, 
Louis DN, Wiestler O D (1994): Deletion mapping of chromosome 
19 in human gliomas. Int J Cancer 57: 676-680. 
208. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, 
Mohapatra G, Hosek SM, Kimmel D, O Fallon J, Yates A, 
Feuerstein BG，Burger PC, Scheithauer B W , Jenkins RB (1999): 
Localization of common deletion regions on Ip and 19q in human 
gliomas and their association with histological subtype. Oncogene 
18:4144-4152. 
209. Bigner SH, Matthews MR, Rasheed BK, Wiltskire RN, 
Friedman HS，Friedman AH, Stenzel TT, Dawes D M , Mclendon 
RE, Bigner D D (1999): Molecular genetic aspects of 
oligodendrogliomas including analysis by comparative genomic 
hybridization. A m J Pathol 155:375-386. 
210. Magnani I，Chiariello E, Conti AM, Finocchiaro G (1999): A 
recurrent 19qll-12 breakpoint suggested by cytogenetic and 
fluorescence in situ hybridization analysis of three glioblastoma 
cell lines. Cancer Genet Cytogenet 11:82-86. 
211. Caimcross JG, ueki K, Zlatescu MC, Lisle DK, Finkelstein 
D M , Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, 
Ramsay DA, Louis D N (1998): Specific genetic predictors of 
Zheng PP 152 
chemotherapeutic response and survival in patients with anaplastic 
oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479. 
212. Kros JM, van Run PR, Alers JC, Beverloo HB, van den Bent 
MJ, Avezaat CJ, van Dekken H (1999): Genetic aberrations in 
oligodendroglial tumors: an analysis using comparative genomic 
hybridization (CGH). J Pathol 188: 282-288. 
213. Ritland SR, Ganju V，Jenkins RB (1995): Region-specific 
loss of heterozygosity on chromosome 19 is related to the 
morphologic type of human glioma. Genes Chromosomes Cancer 
12: 277-282. 
214. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, 
Sarasa JL, Pestana A, Rey JA (1995): Allelic loss at Ip and 19q 
frequently occurs in association and may represent early oncogenic 
events in oligodendroglial tumors. Int J Cancer 64:207-210. 
215. Rubio MP, Correa KM, Ueki K, Mohren Weiser H W , 
Gusella JF, von Deimling A, Louis D N (1994): The putative 
glioma tumor suppressor gene on chromosome 19q maps between 
AP0C2 and HRC. Cancer Res 54: 4760-4763. 
216. von Deimling A, Bender B, jahnkek K, Waha A, Kraus J, 
Albrecht S，Wellenreuther R, Fassbebder F, Nagel J, Menon A G 
(1994): Loci associated with malignant progression in 
Zheng PP 153 
astrocytomas: a candidate on chromosome 19q. Cancer Res 15; 
54:1397-1401. 
217. Roulston D, Espinosa R 3d, Stoffel M, Bell GI, Le Beau 
M M (1993): Molecular genetics of myloid leukemia: identification 
of the commonly deleted segment of chromosome 20. Blood 82 : 
3424-3429. 
218. Wang PW，Eisenbart JD, Cordes SP, Barsh GS, Stoffel M, 
Le Beau M M (1999): Human K R M L (MABF): cDNA cloning, 
genomic structure, and evaluation as a candidate tumor suppressor 
gene in myloid leukemias. Genomic 59: 275-281. 
219. Asimakopoulos FA, Green A R (1996): Deletions of 
chromosome 20q and pathogenesis of myeloproliferative disorders. 
Br J Haematol 95 : 219-226. 
220. Roulston D，Espinosa R 3d, Stoffel M, Bell GI, Le Beau 
M M (1993): Molecular genetics of myloid leukemia: identification 
of the commonly deleted segment of chromosome 20. Blood 82 : 
3424-3429. 
221. Nacheva E, Holloway T, Carter N, Grace C, White N, Green 
A R (1995): Characterization of 20 q deletions in patients with 
myeloproliferative disorders or myelodysplastic syndromes. 
Cancer Genet cytogenet 80 : 87-94. 
Zheng PP 154 
222. Rollings PE (1994): Molecular heterogeneity at the 
breakpoints of smaller 20q deletions. Genes chromosomes Cancer 
11 : 21-28. 
223. Silengo M, Vassallo E, Barisone E, Miniero R, Madon E 
(1992): Monosomy 20 in childhood acute lymphoblastic leukemia. 
Cancer Genet Cytogenet 59 : 177-179. 
224. Cougue N, Chambon-Pautas C, Cave H, Bardet V, Daval M. 
Vilmer E，Grandchamp B (1999): Mapping of chromosome 20 for 
loss of heterozygosity in childhood ALL reveals a 1,000-kb 
deletion in one patient. Leukemia 13 : 1972-1974. 
225. Nori H, Tawara M, Yoshida Y, Kuriyama K，Sugihara K, 
Kamihira S, Tomonaga M (2000): Minimally differentiated acute 
myeloid leukemia (AML-MO) with extensive erythrophagocytosis 
and del (20)(ql 1) chromosome abnormalitiy. Leuk Res 24: 87-90. 
226. Mohapatra G, Kim DH, Feuerstein B G (1995): Detection of 
multiple gains and losses of genetic material in ten glioma cell 
lines by comparative genomic hybridization. Genes Chromosomes 
Cancers 13: 86-93. 
227. Kim DH, Mohapatra G, Bollen A, Waldman FM, Feuerstein 
B G (1995): Chromosomal abnormalities in glioblastoma 
multiforme tumors and glioma cell lines detected by comparative 
genomic hybridization. Int J Cancer 60 : 812-819. 
Zheng PP 155 
228. Schrock E, Thiel G, Lozanova T, du Manoir S, Meffert MC, 
Jauch A, Speicher MR, Numberg P, Vogel S, Janishch W (1994): 
Comparative genomic hybridization of human malignant gliomas 
reveals multiple amplification sites and nonrandom chromosomal 
gains and losses. A m J Pathol 144: 1203-1218. 
229. Westphal M, Hansel M, Hamel W, Kunzmann R, Holzel F 
(1994): Karyotype analyses of 20 human glioma cell lines. Acta 
Neurochir 126:17-26. 
230. Bello MJ, de Campos JM, Kusak ME, Vaquero H, Sarasa JL, 
Petana A, Rey JA (1994): Ascertainment of chromosome 7 gains in 
malignant gliomas by cytogenetic and RFLP analyses. Cancer 
Genet Cytogenet 72: 55-58. 
231. Rey JA, Bello MJ, de Campos JM, Kusak ME, Ramos C, 
Benitez J (1987): Chromosomal patterns in human malignant 
astrocytomas. Cancer Genet Cytogenet 29: 201-221. 
232. Schrock E, Blume C, Meffert MC, du manoir S, Bersch W, 
Kiessling M, Lozanowa T, Thiel G, Witkowski R, Ried T, Cremer 
M T (1996): Recurrent gain chromosome arm 7q in low-grade 
astrocytic tumors studied by comparative genomic hybridization. 
Genes Chromosomes Cancer 15: 199-205. 
Zheng PP 156 
233. James CD, Carlbom E, Dumanski JP, Hansen M, 
Nordenskjold M, Collin VP, Cavenee W K (1988): Clonal genomic 
alterations in glioma malignancy stages. Cancer Res 48:5546-5551. 
234. Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, 
Pestana A, Rey JA (1994): Molecular analysis of genomic 
abnormalities in human gliomas. Cancer Genet Cytogenet 73: 122-
129. 
235. Bemell P, Arbidsson I, Jacobosson B (1999): Gain of 
chromosome 7，which marks the progression from indolent to 
aggressive follicle center lymphomas, is restricted to the B-
lymphoid lineage: a study by FISH in combination with 
morphology and immunocytochemistry. Br J Hematol 105: 1140-
1144。 
236. Schmidt H, Wurl P, Taubert H, Meye A, Bache M, 
Holzhausen HJ, Hinze R (1999): Genomic imbalances of 7p and 
17q in malignant peripheral nerve sheath tumors are clinically 
relevant. Genes Chromosomes Cancer 25: 205-211。 
237. Saucer T, Beraki K, Jebsen PW, Naess O (1999): Numerical 
abnormalities of chromosme 7 in interphase cell nuclei of breast 
carcinoma have no impact on immunohistochemically determined 
EGFR status. APMIS 107: 211-216. 
Zheng PP 157 
238. Roque L, Serpa A, Clode A, Castedo S, Scares J (1999): 
Significance of trisomy 7 and 12 in thyroid lesions with follicular 
differentiation: a cytogenetic and in situ hybridization study. Lab 
Invest 79: 369-378. 
239. Liu L, Ichimura K, Pettersson EH, Collins VP (1998): 
Chromosome 7 rearrangements in glioblastomas; loci adjacent to 
EGFR are independently amplified. J Neuropathol Exp Neurol 57: 
1138-1145. 
240. Hirata K, Tagawa Y, Kashima K, Kidogawa H, Deguchi M, 
Tsuji T, Ayabe H (1998): Frequency of chromosome 7 gain in 
human breast cancer cells: correlation with the number of 
metastatic lymph nodes and prognosis. J Exp Med 184:85-97. 
241. Ahmed MN, Kim K, Haddad B, berchuck A, Qumsiyeh M B 
(1997): Comparative genomic hybridization studies in 
hydatidiform moles and choriocarcinoma: amplification of 7q21-
31 and loss of 8p 12-21 in choriocarcinoma. Cancer Genet 
Cytogenet 116: 10-15. 
242. Finelli P, Giardino D, Rizzi N, Buiatotis S, Virduci T, 
Franzin A, Losa M, Larizza L (2000): Non-random trisomies of 
chromosomes 5, 8 and 12 in the prolactinoma sub-type of pituitary 
adenomas: conventional cytogenetics and interphase FISH study. 
Int J Cancer 86:344-50. 
Zheng PP 158 
243. Suzuki SO and Iwaki T (2000): Amplification and 
overexpression of mdm2 gene in ependymomas. Mod Pathol 
13:548-53. 
244. Russell AJ, Sibbald J, Haak H, Keith W W , McNicol A M 
(1999): Increasing genome instability in adrenocortical carcinoma 
progression with involvement of chromosomes 3, 9 and X at the 
adenoma stage. Br J Cancer 81: 684-689. 
245. Chen Z, Notohamiprodjo M, Guan XY, Paietta E, Blackwell 
S, Stout K, Turner A, Richkind K, Trent JM, Lamb A, Sandberg 
A A (1998): Gain of 9p in the pathogenesis of polycythemia vera. 
Genes Chromosomes Cancer 22: 321-324. 
246. Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, 
Ward D C (1999): Fragment chromosomal D N A unbalance in 
thyroid oncocytic (Hurthle cell) neoplasms detected by 
comparative genomic hybridization. Lab Invest 79: 547-555. 
247. Kenck C, Bugert P, Wilhelm M, Kovacs G (1997): 
Duplication of an approximately 1.5 M B D N A segment at 
chromosome 5q22 indicates the locus of a new tumor gene in non-
papillary renal carcinoma. Oncogene 14: 1093-1098. 
248. Bemd VJ, Romeike FM, henn W, Feiden W, Moringlane JR, 
Zang KD, Urbschat S (1999): Evidence of focal genetic 
microheterogeneity in glioblastoma multiforme by area-specific 
Zheng PP 159 
C G H on microdissected tumor cells. J Neuropatho Exp Neuro 58 : 
993-999. 
249. Kappler R, Schlegel J, Kindler-Rohrbom A, Mennel H, 
Scherthan H (1999): Comparative genomic in situ hybridization 
discloses recurrent gain of chromosome 4 in experimental gliomas 
of the rat. Cytogenet Cell Genet 84: 194-198. 
..；-:；• . 
CUHK L i b r a r i e s 
0D3fi72MT0 
